https://gate.unigre.it/mediawiki/index.php?action=history&feed=atom&title=5F-ADB-PINACA_Wikipedia 2026-05-30T13:27:42Z Revision history for this page on the wiki MediaWiki 1.35.7 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=149047&oldid=prev 2026-05-28T19:26:14Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:26, 28 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">A 30</del>-<del class="diffchange diffchange-inline">min period</del>, <del class="diffchange diffchange-inline">beginning when maximal depression of locomotor activity first appeared as </del>a <del class="diffchange diffchange-inline">function of dose</del>, <del class="diffchange diffchange-inline">was used for analysis of dose</del>-<del class="diffchange diffchange-inline">response data and calculation </del>of <del class="diffchange diffchange-inline">ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to 4F ADB reinforcement. The substitution tests occurred only if the rats had achieved 85% injection</del>-<del class="diffchange diffchange-inline">appropriate responding on the two prior training sessions.&lt;br&gt;The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive </del>effects<del class="diffchange diffchange-inline">, which is useful for identifying parameters for drug discrimination experiments </del>and <del class="diffchange diffchange-inline">are also predictive of the time course of the psychoactive effects in human users</del>. The <del class="diffchange diffchange-inline">purpose </del>of the <del class="diffchange diffchange-inline">present study was to assess </del>the <del class="diffchange diffchange-inline">abuse liability of 5F</del>-<del class="diffchange diffchange-inline">MDMB-PINACA</del>, <del class="diffchange diffchange-inline">MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. Since there is currently </del>no <del class="diffchange diffchange-inline">robust measure of the reinforcing/rewarding effects of cannabinoids</del>, <del class="diffchange diffchange-inline">drug discrimination is currently the best model for assessing abuse liability </del>of <del class="diffchange diffchange-inline">cannabinoids. The findings produce an apparent paradox</del>, <del class="diffchange diffchange-inline">since CPP </del>and <del class="diffchange diffchange-inline">self-administration predict with high reliability the likelihood that </del>a <del class="diffchange diffchange-inline">compound will be abused by humans, and </del>cannabinoids <del class="diffchange diffchange-inline">are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;&lt;br&gt;Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con</del>. All <del class="diffchange diffchange-inline">groups treated with tested synthetic cannabinoids showed decreased weight gain rate in a dose-dependent manner. A total </del>of <del class="diffchange diffchange-inline">5 mice in </del>the <del class="diffchange diffchange-inline">JWH-081 (5 mg/kg, i.p.) treated group and 6 mice </del>in the <del class="diffchange diffchange-inline">4F ADB JWH-210 (5 mg/kg, i.p.) treated group showed loss of traction, of which 4 and 5 showed tremor, respectively. Memory retention was measured after the memory acquisition was tested </del>as <del class="diffchange diffchange-inline">a probe trial.&lt;br&gt;About Powder JWH-2&lt;br&gt;&lt;br&gt;One recent study has looked at </del>other <del class="diffchange diffchange-inline">mechanisms of action in some of the older </del>synthetic cannabinoids <del class="diffchange diffchange-inline">and reported that some produced varying amounts of activity at sites which are related to cardiotoxicity and heart disease </del>(Wiley et al., <del class="diffchange diffchange-inline">2016&lt;br&gt;&lt;br&gt;&lt;br&gt;The same procedure was then applied to the mice once every day for 5 days</del>. <del class="diffchange diffchange-inline">It was considered </del>as <del class="diffchange diffchange-inline">coordination disturbance when mice fell from the test apparatus within 2 </del>min. <del class="diffchange diffchange-inline">Mice that remained their position on the running apparatus at </del>10 <del class="diffchange diffchange-inline">rpm for at least 2 </del>min were <del class="diffchange diffchange-inline">selected for further evaluation</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Table of Conten</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Male ND4 Swiss–Webster mice were obtained </del>from <del class="diffchange diffchange-inline">Envigo (Houston</del>, <del class="diffchange diffchange-inline">TX) at approximately 8 weeks </del>of <del class="diffchange diffchange-inline">age </del>and <del class="diffchange diffchange-inline">maintained in </del>the <del class="diffchange diffchange-inline">University </del>of <del class="diffchange diffchange-inline">North Texas Health Science Center </del>(<del class="diffchange diffchange-inline">UNTHSC</del>) <del class="diffchange diffchange-inline">animal facility for two weeks prior to testin&lt;br&gt;&lt;br&gt;A systematic review including data </del>of <del class="diffchange diffchange-inline">114 patients </del>of <del class="diffchange diffchange-inline">which </del>the <del class="diffchange diffchange-inline">majority was intoxicated due to </del>SCRA <del class="diffchange diffchange-inline">smoking revealed that 45 % </del>of the <del class="diffchange diffchange-inline">patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not [https://cannabinoidsrc4f-adb.com/ <del class="diffchange diffchange-inline">4F ADB</del>] retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse </del>(<del class="diffchange diffchange-inline">DOA</del>) <del class="diffchange diffchange-inline">test was initially performed on the urine of the patient</del>. He confirmed <del class="diffchange diffchange-inline">drinking 750 ml energy drink without any further consumption of food and using </del>an e-cigarette <del class="diffchange diffchange-inline">from Gaziantep, Turkey 10 seconds </del>before the onset of his <del class="diffchange diffchange-inline">first </del>symptoms. <del class="diffchange diffchange-inline">He usually smokes a pack of cigarettes a day </del>and <del class="diffchange diffchange-inline">sometimes smokes e-cigarettes</del>. <del class="diffchange diffchange-inline">Combined with non</del>-<del class="diffchange diffchange-inline">specific</del>, <del class="diffchange diffchange-inline">transient symptoms, clinical recognition </del>of SCRA <del class="diffchange diffchange-inline">intoxication is challenging .</del>&lt;br&gt;<del class="diffchange diffchange-inline">Data availability </del>&lt;br&gt;The <del class="diffchange diffchange-inline">intensity </del>is <del class="diffchange diffchange-inline">plotted against </del>the <del class="diffchange diffchange-inline">retention </del>time for <del class="diffchange diffchange-inline">both chromatograms, demonstrating </del>the <del class="diffchange diffchange-inline">4F ADB presence and elution profiles </del>of <del class="diffchange diffchange-inline">nicotine and ADB-BUTINACA </del>in the <del class="diffchange diffchange-inline">analysed vape liquid sample</del>. <del class="diffchange diffchange-inline">LC-QTOF-MS Chromatograms </del>of <del class="diffchange diffchange-inline">Nicotine </del>(<del class="diffchange diffchange-inline">Top</del>) <del class="diffchange diffchange-inline">and ADB-BUTINACA </del>(<del class="diffchange diffchange-inline">Bottom</del>) <del class="diffchange diffchange-inline">in </del>the <del class="diffchange diffchange-inline">Vape Liquid used by </del>the <del class="diffchange diffchange-inline">patient</del>. <del class="diffchange diffchange-inline">The LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS analysis showed that the e</del>-<del class="diffchange diffchange-inline">liquid contained nicotine </del>and <del class="diffchange diffchange-inline">ADB</del>-<del class="diffchange diffchange-inline">BUTINACA (Fig. </del>1<del class="diffchange diffchange-inline">)</del>. <del class="diffchange diffchange-inline">Because the point-</del>of<del class="diffchange diffchange-inline">-care DOA </del>test <del class="diffchange diffchange-inline">is generally not able </del>to <del class="diffchange diffchange-inline">detect synthetic recreational drug substances, </del>the <del class="diffchange diffchange-inline">liquid of </del>the <del class="diffchange diffchange-inline">e-cigarette was thereafter screened using liquid chromatography-quadrupole time-</del>of<del class="diffchange diffchange-inline">-flight mass spectrometry </del>(<del class="diffchange diffchange-inline">LC-QTOF-MS</del>) <del class="diffchange diffchange-inline">on </del>the <del class="diffchange diffchange-inline">Waters™ Xevo G3 QTOF MS system</del>. <del class="diffchange diffchange-inline">After eating a light meal </del>and <del class="diffchange diffchange-inline">drinking caffeinated sports drinks at </del>the <del class="diffchange diffchange-inline">ER, the nausea complaints </del>of <del class="diffchange diffchange-inline">the patient </del>were <del class="diffchange diffchange-inline">reduced and the patient was discharged hom</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">4. Drugs &lt;br&gt;Short</ins>-<ins class="diffchange diffchange-inline">onset</ins>, <ins class="diffchange diffchange-inline">short-acting compounds have </ins>a <ins class="diffchange diffchange-inline">greater abuse liability</ins>, <ins class="diffchange diffchange-inline">and long</ins>-<ins class="diffchange diffchange-inline">acting compounds pose problems </ins>of <ins class="diffchange diffchange-inline">long</ins>-<ins class="diffchange diffchange-inline">acting adverse </ins>effects and <ins class="diffchange diffchange-inline">interactions with other drugs</ins>. The <ins class="diffchange diffchange-inline">duration of action </ins>of the <ins class="diffchange diffchange-inline">synthetic cannabinoids tested using </ins>the <ins class="diffchange diffchange-inline">8</ins>-<ins class="diffchange diffchange-inline">h protocol have varied widely</ins>, <ins class="diffchange diffchange-inline">with some producing a duration of action </ins>no <ins class="diffchange diffchange-inline">longer than 1 h</ins>, <ins class="diffchange diffchange-inline">others producing a duration </ins>of <ins class="diffchange diffchange-inline">action between 1–2 h</ins>, and <ins class="diffchange diffchange-inline">others lasting more than 2 h. There seems to be </ins>a <ins class="diffchange diffchange-inline">trend of newer synthetic </ins>cannabinoids <ins class="diffchange diffchange-inline">being more potent than earlier compounds</ins>. All of the <ins class="diffchange diffchange-inline">compounds tested </ins>in the <ins class="diffchange diffchange-inline">present study depressed locomotor activity </ins>as <ins class="diffchange diffchange-inline">is typical for </ins>other synthetic cannabinoids (<ins class="diffchange diffchange-inline">see review by </ins>Wiley et al., <ins class="diffchange diffchange-inline">2017)</ins>. <ins class="diffchange diffchange-inline">Average horizontal activity counts/10 min </ins>as <ins class="diffchange diffchange-inline">a function of time (10 </ins>min <ins class="diffchange diffchange-inline">bins) and dose</ins>. <ins class="diffchange diffchange-inline">Depressant effects of 1.33 mg/kg were observed within </ins>10 min <ins class="diffchange diffchange-inline">following administration and peak depressant effects </ins>were <ins class="diffchange diffchange-inline">observed between 0–30 min</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Michael B Gat&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating </ins>from <ins class="diffchange diffchange-inline">prisoners</ins>, <ins class="diffchange diffchange-inline">teenagers and test purchases </ins>of <ins class="diffchange diffchange-inline">commercially available e-cigarettes taken between 2014 </ins>and <ins class="diffchange diffchange-inline">2021 . This is the first case report that describes </ins>the <ins class="diffchange diffchange-inline">toxicological symptoms of vaping ADB-BUTINACA. Results </ins>of <ins class="diffchange diffchange-inline">the DOA test </ins>(<ins class="diffchange diffchange-inline">including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants</ins>) <ins class="diffchange diffchange-inline">were available within 30 minutes and were all negative. We report a case </ins>of <ins class="diffchange diffchange-inline">an involuntary intoxication </ins>of the SCRA <ins class="diffchange diffchange-inline">ADB-BUTINACA after vaping. There are several pitfalls in the detection </ins>of <ins class="diffchange diffchange-inline">SCRA in samples taken from </ins>the <ins class="diffchange diffchange-inline">patient.&lt;br&gt;Data availabili</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not [https://cannabinoidsrc4f-adb.com/ <ins class="diffchange diffchange-inline">JWH-210 powder</ins>] retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">As synthetic cannabinoid receptor agonists </ins>(<ins class="diffchange diffchange-inline">SCRA</ins>) <ins class="diffchange diffchange-inline">are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests</ins>. He confirmed <ins class="diffchange diffchange-inline">that he had been vaping </ins>an <ins class="diffchange diffchange-inline">electronic cigarette (</ins>e-cigarette<ins class="diffchange diffchange-inline">) earlier that day just </ins>before the onset of his symptoms. <ins class="diffchange diffchange-inline">Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation </ins>and <ins class="diffchange diffchange-inline">ventilation for one case</ins>. <ins class="diffchange diffchange-inline">In 3 cases ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA was the only substance detected</ins>, <ins class="diffchange diffchange-inline">while in seven other substances </ins>of <ins class="diffchange diffchange-inline">misuse were also detected including other </ins>SCRA<ins class="diffchange diffchange-inline">, opioids, benzodiazepines cocaine and pregabali</ins>&lt;br&gt;&lt;br&gt;The <ins class="diffchange diffchange-inline">locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects, which </ins>is <ins class="diffchange diffchange-inline">useful for identifying parameters for drug discrimination experiments and are also predictive of </ins>the time <ins class="diffchange diffchange-inline">course of the psychoactive effects in human user&lt;br&gt;&lt;br&gt;&lt;br&gt;Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges </ins>for the <ins class="diffchange diffchange-inline">drug discrimination assay were selected based on the time </ins>of <ins class="diffchange diffchange-inline">peak depression </ins>in the <ins class="diffchange diffchange-inline">locomotor activity assay in mice</ins>. <ins class="diffchange diffchange-inline">Average potency of the discriminative stimulus effects </ins>of <ins class="diffchange diffchange-inline">early compounds was 0.81±0.17 mg/kg </ins>(<ins class="diffchange diffchange-inline">Gatch et al., 2014</ins>)<ins class="diffchange diffchange-inline">, whereas the potency of a recent set was 0.09±0.03 mg/kg </ins>(<ins class="diffchange diffchange-inline">Gatch et al., 2018</ins>)<ins class="diffchange diffchange-inline">, and </ins>the <ins class="diffchange diffchange-inline">potency of </ins>the <ins class="diffchange diffchange-inline">current set is 0.05±0.01 mg/kg</ins>. <ins class="diffchange diffchange-inline">Short</ins>-<ins class="diffchange diffchange-inline">onset, short</ins>-<ins class="diffchange diffchange-inline">acting compounds have a greater abuse liability, and long-acting compounds pose problems of long</ins>-<ins class="diffchange diffchange-inline">acting adverse effects </ins>and <ins class="diffchange diffchange-inline">interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8</ins>-<ins class="diffchange diffchange-inline">h protocol have varied widely, with some producing a duration of action no longer than </ins>1 <ins class="diffchange diffchange-inline">h, others producing a duration of action between 1–2 h, and others lasting more than 2 h</ins>. <ins class="diffchange diffchange-inline">There seems to be a trend </ins>of <ins class="diffchange diffchange-inline">newer synthetic cannabinoids being more potent than earlier compound&lt;br&gt;&lt;br&gt;&lt;br&gt;Morris water maze </ins>test <ins class="diffchange diffchange-inline">was performed </ins>to <ins class="diffchange diffchange-inline">evaluate </ins>the <ins class="diffchange diffchange-inline">changes in learning and memory function. Only a few case reports about </ins>the <ins class="diffchange diffchange-inline">dangers </ins>of <ins class="diffchange diffchange-inline">some synthetic cannabinoids due to neurotoxicity have been published </ins>(<ins class="diffchange diffchange-inline">Cohen et al., 2012; McGuinness et al., 2012; Harris and Brown, 2013; Hermanns et al., 2013</ins>)<ins class="diffchange diffchange-inline">. In addition, </ins>the <ins class="diffchange diffchange-inline">lack of information about neurotoxicity of synthetic cannabinoids could allow abusers consume those substances undiscerningly</ins>. <ins class="diffchange diffchange-inline">However, slight structural changes might cause biochemical properties including dependence liability </ins>and <ins class="diffchange diffchange-inline">neurotoxicity. The substances used in </ins>the <ins class="diffchange diffchange-inline">present study both possess naphthoylindole moiety as their parental structure. (B) The ratio </ins>of <ins class="diffchange diffchange-inline">damaged cells containing pyknotic or condensed nuclei and low hematoxilin affinity to total cells </ins>were <ins class="diffchange diffchange-inline">calculated in nucleus accumben</ins></div></td></tr> <!-- diff cache key my_wiki:diff::1.12:old-149026:rev-149047 --> </table>

ISZCindy643869 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=149026&oldid=prev 2026-05-28T19:17:58Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:17, 28 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Acute kidney damage </del>and <del class="diffchange diffchange-inline">even kidney failure have been reported following use </del>of <del class="diffchange diffchange-inline">synthetic cannabinoids (Davidson</del>, <del class="diffchange diffchange-inline">et al.</del>, <del class="diffchange diffchange-inline">2017)</del>. <del class="diffchange diffchange-inline">One recent study has looked at other mechanisms of action in some of </del>the <del class="diffchange diffchange-inline">older synthetic cannabinoids </del>and <del class="diffchange diffchange-inline">reported that some produced varying amounts </del>of <del class="diffchange diffchange-inline">activity at sites </del>which are <del class="diffchange diffchange-inline">related to cardiotoxicity and heart disease (Wiley et al</del>.<del class="diffchange diffchange-inline">, 2016). It is not known whether </del>the <del class="diffchange diffchange-inline">increased toxicity is due only </del>to <del class="diffchange diffchange-inline">activation </del>of <del class="diffchange diffchange-inline">CB1 cannabinoid receptors more strongly than Δ9</del>-<del class="diffchange diffchange-inline">THC or whether these &quot;super</del>-<del class="diffchange diffchange-inline">strength&quot; cannabinoids produce </del>effects <del class="diffchange diffchange-inline">at other receptors. A major cause </del>of <del class="diffchange diffchange-inline">concern </del>is <del class="diffchange diffchange-inline">that some </del>of the <del class="diffchange diffchange-inline">more recently seen synthetic </del>cannabinoids are <del class="diffchange diffchange-inline">more likely </del>to produce <del class="diffchange diffchange-inline">extremely toxic effects than the older synthetics (Tai and Fantegrossi, 2017</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">In summary, JWH-210 Chemical Powder stands out as </del>a <del class="diffchange diffchange-inline">high</del>-<del class="diffchange diffchange-inline">quality research compound designed for professionals who demand accuracy, consistency, and reliability</del>. <del class="diffchange diffchange-inline">This commitment to 5CLADBA quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage </del>of the <del class="diffchange diffchange-inline">process is monitored to ensure compliance with laboratory</del>-<del class="diffchange diffchange-inline">grade expectations</del>. <del class="diffchange diffchange-inline">This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards</del>.<del class="diffchange diffchange-inline">&lt;br&gt;Key Features </del>and <del class="diffchange diffchange-inline">Specifications to Evaluate &lt;br&gt;In case of cannabis or Δ9</del>-<del class="diffchange diffchange-inline">tetrahydrocannabinol, there are many [https:</del>/<del class="diffchange diffchange-inline">/cannabinoidsrc4f-adb.com/ 5CLADBA] previous studies regarding with their dependence potential and neurotoxicity (Cororan</del>, <del class="diffchange diffchange-inline">et al</del>.<del class="diffchange diffchange-inline">, 1974; Harris, et al</del>.<del class="diffchange diffchange-inline">, 1974; Leite and Culini, 1974; Hutcheson, et al., 1998</del>)<del class="diffchange diffchange-inline">. After administering test substances once every other day for 10 days</del>, <del class="diffchange diffchange-inline">brain samples </del>of <del class="diffchange diffchange-inline">mice were collected, especially at nucleus accumbens </del>and <del class="diffchange diffchange-inline">hippocampus regions. Drug was administered </del>5 <del class="diffchange diffchange-inline">times every other day</del>, <del class="diffchange diffchange-inline">and the first trial </del>was <del class="diffchange diffchange-inline">performed 2 h </del>after the <del class="diffchange diffchange-inline">last administration</del>.&lt;br&gt;<del class="diffchange diffchange-inline">How to Choose </del>Powder JWH-<del class="diffchange diffchange-inline">210 </del>&lt;br&gt;<del class="diffchange diffchange-inline">This dual-use nature underscores </del>the <del class="diffchange diffchange-inline">importance </del>of <del class="diffchange diffchange-inline">responsible sourcing and strict adherence </del>to <del class="diffchange diffchange-inline">legal frameworks. Forensic labs, public health researchers, </del>and <del class="diffchange diffchange-inline">customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials</del>. <del class="diffchange diffchange-inline">For those seeking a dependable compound for analytical purposes</del>, <del class="diffchange diffchange-inline">JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based researc</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">A total of 2 and 3 methamphetamine treated </del>mice fell from the <del class="diffchange diffchange-inline">spinning rod 30 </del>min <del class="diffchange diffchange-inline">and </del>2 <del class="diffchange diffchange-inline">hr after the administration, respectively</del>. <del class="diffchange diffchange-inline">After the first injection</del>, <del class="diffchange diffchange-inline">6 mice </del>of the <del class="diffchange diffchange-inline">positive control group </del>(<del class="diffchange diffchange-inline">methamphetamine, 5 mg/kg, i.p.</del>) <del class="diffchange diffchange-inline">showed loss </del>of <del class="diffchange diffchange-inline">traction, </del>of which <del class="diffchange diffchange-inline">4 showed tremor. Most </del>of the <del class="diffchange diffchange-inline">abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from </del>the <del class="diffchange diffchange-inline">mice </del>after <del class="diffchange diffchange-inline">the last administration of test substance</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">LC separates the urine or </del>blood <del class="diffchange diffchange-inline">sample </del>and <del class="diffchange diffchange-inline">QTOF-MS provides </del>high-resolution <del class="diffchange diffchange-inline">and </del>accurate mass <del class="diffchange diffchange-inline">measurements for precise identification and structural elucidation of compounds</del>. The <del class="diffchange diffchange-inline">LC</del>-<del class="diffchange diffchange-inline">QTOF</del>-<del class="diffchange diffchange-inline">MS method offers </del>a <del class="diffchange diffchange-inline">more comprehensive and sensitive approach for </del>drug <del class="diffchange diffchange-inline">detection</del>, <del class="diffchange diffchange-inline">covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge </del>the drug <del class="diffchange diffchange-inline">aerolisation and bioavailability, one can elevate </del>the <del class="diffchange diffchange-inline">flow rate </del>of <del class="diffchange diffchange-inline">air through </del>the e-cigarette <del class="diffchange diffchange-inline">and/or add a diluent </del>. Of <del class="diffchange diffchange-inline">all e-cigarette users registered at this forum</del>, <del class="diffchange diffchange-inline">7.8 % vaped </del>SCRAs <del class="diffchange diffchange-inline">. About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong</del>, <del class="diffchange diffchange-inline">together with synthetic opioids</del>, <del class="diffchange diffchange-inline">cathinones, amphetamines </del>and <del class="diffchange diffchange-inline">hallucinogens to </del>the <del class="diffchange diffchange-inline">new psychoactive substances (</del>NPS<del class="diffchange diffchange-inline">) that are currently developed at high speed</del>.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;LC-QTOF-MS <del class="diffchange diffchange-inline">represents a significant advancement in </del>the <del class="diffchange diffchange-inline">field of drug </del>detection<del class="diffchange diffchange-inline">, offering higher sensitivity, specificity, </del>and a <del class="diffchange diffchange-inline">broader </del>spectrum of <del class="diffchange diffchange-inline">detectable </del>substances. <del class="diffchange diffchange-inline">Despite all negative results in the </del>point-of-care <del class="diffchange diffchange-inline">test for recreational </del>drugs<del class="diffchange diffchange-inline">, the liquid chromatography-quadrupole time-</del>of<del class="diffchange diffchange-inline">-flight mass spectrometry </del>(<del class="diffchange diffchange-inline">LC-QTOF-MS</del>) <del class="diffchange diffchange-inline">analysis showed that </del>the <del class="diffchange diffchange-inline">liquid </del>of the e-cigarette <del class="diffchange diffchange-inline">contained ADB-BUTINACA</del>, a <del class="diffchange diffchange-inline">synthetic cannabinoid. We report </del>a <del class="diffchange diffchange-inline">27</del>-<del class="diffchange diffchange-inline">year</del>-<del class="diffchange diffchange-inline">old man who was admitted to the emergency room because of sudden 5CLADBA headache</del>, <del class="diffchange diffchange-inline">nausea</del>, <del class="diffchange diffchange-inline">vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection </del>is <del class="diffchange diffchange-inline">not commonly available</del>.&lt;br&gt;Data availability &lt;br&gt;<del class="diffchange diffchange-inline">When clinical presentation </del>and<del class="diffchange diffchange-inline">/or initial DOA testing results are inconclusive, additional testing with </del>LC-QTOF-MS <del class="diffchange diffchange-inline">can be valuable </del>and <del class="diffchange diffchange-inline">is recommended</del>. <del class="diffchange diffchange-inline">SCRAs </del>and <del class="diffchange diffchange-inline">other NPS may not be detected by point</del>-<del class="diffchange diffchange-inline">of-care DOA tests</del>. <del class="diffchange diffchange-inline">In this case, </del>the point-of-care DOA <del class="diffchange diffchange-inline">urine screening was </del>not able to detect the <del class="diffchange diffchange-inline">synthetic cannabinoid ADB</del>-<del class="diffchange diffchange-inline">BUTINAC</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data </ins>and <ins class="diffchange diffchange-inline">calculation </ins>of <ins class="diffchange diffchange-inline">ED50 values. During test sessions</ins>, <ins class="diffchange diffchange-inline">both levers were active</ins>, <ins class="diffchange diffchange-inline">such that ten consecutive responses on either lever led to 4F ADB reinforcement</ins>. <ins class="diffchange diffchange-inline">The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on </ins>the <ins class="diffchange diffchange-inline">two prior training sessions.&lt;br&gt;The locomotor activity assay was used to identify approximate time courses </ins>and <ins class="diffchange diffchange-inline">dose ranges </ins>of <ins class="diffchange diffchange-inline">psychoactive effects, </ins>which <ins class="diffchange diffchange-inline">is useful for identifying parameters for drug discrimination experiments and </ins>are <ins class="diffchange diffchange-inline">also predictive of the time course of the psychoactive effects in human users</ins>. <ins class="diffchange diffchange-inline">The purpose of </ins>the <ins class="diffchange diffchange-inline">present study was </ins>to <ins class="diffchange diffchange-inline">assess the abuse liability </ins>of <ins class="diffchange diffchange-inline">5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB</ins>-<ins class="diffchange diffchange-inline">FUBINACA, and AMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA. Since there is currently no robust measure of the reinforcing/rewarding </ins>effects of <ins class="diffchange diffchange-inline">cannabinoids, drug discrimination </ins>is <ins class="diffchange diffchange-inline">currently the best model for assessing abuse liability </ins>of <ins class="diffchange diffchange-inline">cannabinoids. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability </ins>the <ins class="diffchange diffchange-inline">likelihood that a compound will be abused by humans, and </ins>cannabinoids are <ins class="diffchange diffchange-inline">well-known </ins>to produce <ins class="diffchange diffchange-inline">active drug-seeking in human</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate in </ins>a <ins class="diffchange diffchange-inline">dose</ins>-<ins class="diffchange diffchange-inline">dependent manner</ins>. <ins class="diffchange diffchange-inline">A total </ins>of <ins class="diffchange diffchange-inline">5 mice in </ins>the <ins class="diffchange diffchange-inline">JWH</ins>-<ins class="diffchange diffchange-inline">081 (5 mg/kg, i</ins>.<ins class="diffchange diffchange-inline">p</ins>.<ins class="diffchange diffchange-inline">) treated group </ins>and <ins class="diffchange diffchange-inline">6 mice in the 4F ADB JWH</ins>-<ins class="diffchange diffchange-inline">210 (5 mg</ins>/<ins class="diffchange diffchange-inline">kg</ins>, <ins class="diffchange diffchange-inline">i</ins>.<ins class="diffchange diffchange-inline">p</ins>.) <ins class="diffchange diffchange-inline">treated group showed loss of traction</ins>, of <ins class="diffchange diffchange-inline">which 4 </ins>and 5 <ins class="diffchange diffchange-inline">showed tremor</ins>, <ins class="diffchange diffchange-inline">respectively. Memory retention </ins>was <ins class="diffchange diffchange-inline">measured </ins>after the <ins class="diffchange diffchange-inline">memory acquisition was tested as a probe trial</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">About </ins>Powder JWH-<ins class="diffchange diffchange-inline">2&lt;br&gt;</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">One recent study has looked at other mechanisms of action in some of </ins>the <ins class="diffchange diffchange-inline">older synthetic cannabinoids and reported that some produced varying amounts </ins>of <ins class="diffchange diffchange-inline">activity at sites which are related </ins>to <ins class="diffchange diffchange-inline">cardiotoxicity </ins>and <ins class="diffchange diffchange-inline">heart disease (Wiley et al</ins>., <ins class="diffchange diffchange-inline">2016</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">The same procedure was then applied to the mice once every day for 5 days. It was considered as coordination disturbance when </ins>mice fell from the <ins class="diffchange diffchange-inline">test apparatus within 2 </ins>min<ins class="diffchange diffchange-inline">. Mice that remained their position on the running apparatus at 10 rpm for at least </ins>2 <ins class="diffchange diffchange-inline">min were selected for further evaluation</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;Table of Conten&lt;br&gt;&lt;br&gt;Male ND4 Swiss–Webster mice were obtained from Envigo (Houston</ins>, <ins class="diffchange diffchange-inline">TX) at approximately 8 weeks </ins>of <ins class="diffchange diffchange-inline">age and maintained in </ins>the <ins class="diffchange diffchange-inline">University of North Texas Health Science Center </ins>(<ins class="diffchange diffchange-inline">UNTHSC</ins>) <ins class="diffchange diffchange-inline">animal facility for two weeks prior to testin&lt;br&gt;&lt;br&gt;A systematic review including data </ins>of <ins class="diffchange diffchange-inline">114 patients </ins>of which <ins class="diffchange diffchange-inline">the majority was intoxicated due to SCRA smoking revealed that 45 % </ins>of the <ins class="diffchange diffchange-inline">patients who present at </ins>the <ins class="diffchange diffchange-inline">ER </ins>after <ins class="diffchange diffchange-inline">an intoxication due to SCRA smoking recovered within 24 hours</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Demographic and clinical features are recorded and </ins>blood and<ins class="diffchange diffchange-inline">/or urine samples analysed using </ins>high-resolution accurate mass <ins class="diffchange diffchange-inline">liquid chromatography-mass spectrometry</ins>. The <ins class="diffchange diffchange-inline">authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not [https://cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb.com/ 4F ADB] retrieve further detailed information about the e</ins>-<ins class="diffchange diffchange-inline">cigarette that was used by the patient such as the label or the region of origin. Whether </ins>a <ins class="diffchange diffchange-inline">recreational </ins>drug <ins class="diffchange diffchange-inline">can be administered via vaping</ins>, <ins class="diffchange diffchange-inline">depends on whether </ins>the drug <ins class="diffchange diffchange-inline">becomes volatile under </ins>the <ins class="diffchange diffchange-inline">evaporation temperature </ins>of the e-cigarette. Of <ins class="diffchange diffchange-inline">these samples</ins>, <ins class="diffchange diffchange-inline">22 contained one or more </ins>SCRAs, <ins class="diffchange diffchange-inline">THC was only detected in 11 samples</ins>, <ins class="diffchange diffchange-inline">only one contained cannabidiol and 6 contained a mixture of THC </ins>and <ins class="diffchange diffchange-inline">cannabidiol. There is difficulty in finding the right information about </ins>the NPS<ins class="diffchange diffchange-inline">, defining their potency and confirmation of their existence in e-liquids or urine samples</ins>.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">High resolution mass spectrometry such as </ins>LC-QTOF-MS <ins class="diffchange diffchange-inline">allows </ins>the detection and <ins class="diffchange diffchange-inline">identification of </ins>a <ins class="diffchange diffchange-inline">broad </ins>spectrum of <ins class="diffchange diffchange-inline">recreational drugs, including new psychoactive </ins>substances. <ins class="diffchange diffchange-inline">A </ins>point-of-care drugs of <ins class="diffchange diffchange-inline">abuse </ins>(<ins class="diffchange diffchange-inline">DOA</ins>) <ins class="diffchange diffchange-inline">test was initially performed on </ins>the <ins class="diffchange diffchange-inline">urine </ins>of the <ins class="diffchange diffchange-inline">patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an </ins>e-cigarette <ins class="diffchange diffchange-inline">from Gaziantep</ins>, <ins class="diffchange diffchange-inline">Turkey 10 seconds before the onset of his first symptoms. He usually smokes </ins>a <ins class="diffchange diffchange-inline">pack of cigarettes </ins>a <ins class="diffchange diffchange-inline">day and sometimes smokes e</ins>-<ins class="diffchange diffchange-inline">cigarettes. Combined with non</ins>-<ins class="diffchange diffchange-inline">specific</ins>, <ins class="diffchange diffchange-inline">transient symptoms</ins>, <ins class="diffchange diffchange-inline">clinical recognition of SCRA intoxication </ins>is <ins class="diffchange diffchange-inline">challenging </ins>.&lt;br&gt;Data availability &lt;br&gt;<ins class="diffchange diffchange-inline">The intensity is plotted against the retention time for both chromatograms, demonstrating the 4F ADB presence and elution profiles of nicotine </ins>and <ins class="diffchange diffchange-inline">ADB-BUTINACA in the analysed vape liquid sample. </ins>LC-QTOF-MS <ins class="diffchange diffchange-inline">Chromatograms of Nicotine (Top) </ins>and <ins class="diffchange diffchange-inline">ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient</ins>. <ins class="diffchange diffchange-inline">The LC-QTOF-MS analysis showed that the e-liquid contained nicotine </ins>and <ins class="diffchange diffchange-inline">ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA (Fig. 1)</ins>. <ins class="diffchange diffchange-inline">Because </ins>the point-of-care DOA <ins class="diffchange diffchange-inline">test is generally </ins>not able to detect <ins class="diffchange diffchange-inline">synthetic recreational drug substances, the liquid of </ins>the <ins class="diffchange diffchange-inline">e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF</ins>-<ins class="diffchange diffchange-inline">MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom</ins></div></td></tr> </table>

RoslynGibson2 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=149010&oldid=prev 2026-05-28T19:11:16Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:11, 28 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">The same procedure was then applied </del>to <del class="diffchange diffchange-inline">the mice once every day for 5 days</del>. It <del class="diffchange diffchange-inline">was considered as coordination disturbance when mice fell from </del>the <del class="diffchange diffchange-inline">test apparatus within 2 min</del>. <del class="diffchange diffchange-inline">Mice </del>that <del class="diffchange diffchange-inline">remained their position on </del>the <del class="diffchange diffchange-inline">running apparatus at 10 rpm for at least 2 min were selected for further evaluation.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Table of Conten</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Tremors were observed in mice 30 minutes following 1 mg/kg AMB</del>-<del class="diffchange diffchange-inline">FUBINACA in the present study</del>. <del class="diffchange diffchange-inline">Pretreatment times and dose ranges </del>for <del class="diffchange diffchange-inline">the drug discrimination assay were selected based on the time </del>of <del class="diffchange diffchange-inline">peak depression in </del>the <del class="diffchange diffchange-inline">locomotor activity assay in mice</del>. <del class="diffchange diffchange-inline">Average potency </del>of <del class="diffchange diffchange-inline">the discriminative stimulus effects of early compounds was 0</del>.<del class="diffchange diffchange-inline">81±0.17 mg</del>/<del class="diffchange diffchange-inline">kg </del>(<del class="diffchange diffchange-inline">Gatch </del>et al., <del class="diffchange diffchange-inline">2014)</del>, <del class="diffchange diffchange-inline">whereas the potency of a recent set was 0</del>.<del class="diffchange diffchange-inline">09±0.03 mg/kg (Gatch </del>et al., <del class="diffchange diffchange-inline">2018</del>), and the <del class="diffchange diffchange-inline">potency of </del>the <del class="diffchange diffchange-inline">current set is 0</del>.<del class="diffchange diffchange-inline">05±0</del>.<del class="diffchange diffchange-inline">01 mg/kg. Short-onset</del>, <del class="diffchange diffchange-inline">short</del>-<del class="diffchange diffchange-inline">acting </del>compounds <del class="diffchange diffchange-inline">have </del>a <del class="diffchange diffchange-inline">greater abuse liability</del>, <del class="diffchange diffchange-inline">and long</del>-<del class="diffchange diffchange-inline">acting compounds pose problems of long-acting adverse effects </del>and <del class="diffchange diffchange-inline">interactions with other drugs</del>. <del class="diffchange diffchange-inline">The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely</del>, <del class="diffchange diffchange-inline">with some producing a duration of action no longer than 1 h</del>, <del class="diffchange diffchange-inline">others producing a duration of action between 1–2 h</del>, <del class="diffchange diffchange-inline">and others lasting more than 2 h. There seems to be </del>a <del class="diffchange diffchange-inline">trend of newer synthetic cannabinoids being more potent than earlier compound</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Such decrease remained </del>2 hr after the administration <del class="diffchange diffchange-inline">(Table 4)</del>. <del class="diffchange diffchange-inline">In locomotor activity</del>, methamphetamine <del class="diffchange diffchange-inline">treated group </del>showed <del class="diffchange diffchange-inline">approximately </del>4.<del class="diffchange diffchange-inline">2 times increase compared to </del>the <del class="diffchange diffchange-inline">negative control </del>treated <del class="diffchange diffchange-inline">group</del>. <del class="diffchange diffchange-inline">Change </del>of <del class="diffchange diffchange-inline">body weight following the treatments with JWH-081 and JWH-210 in mic</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">High </del>resolution mass <del class="diffchange diffchange-inline">spectrometry such as </del>LC-QTOF-MS <del class="diffchange diffchange-inline">allows the </del>detection <del class="diffchange diffchange-inline">and identification of a broad spectrum </del>of recreational drugs, including <del class="diffchange diffchange-inline">new psychoactive substances</del>. <del class="diffchange diffchange-inline">A point-of-care drugs of abuse (DOA) test was initially performed on </del>the <del class="diffchange diffchange-inline">urine </del>of the <del class="diffchange diffchange-inline">patient</del>. <del class="diffchange diffchange-inline">He confirmed drinking 750 ml energy drink without any further consumption of food and using an </del>e-cigarette <del class="diffchange diffchange-inline">from Gaziantep</del>, <del class="diffchange diffchange-inline">Turkey 10 seconds before the onset </del>of <del class="diffchange diffchange-inline">his first symptoms</del>. <del class="diffchange diffchange-inline">He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes</del>. <del class="diffchange diffchange-inline">Combined </del>with <del class="diffchange diffchange-inline">non-specific</del>, <del class="diffchange diffchange-inline">transient symptoms</del>, <del class="diffchange diffchange-inline">clinical recognition of SCRA intoxication is challenging </del>.&lt;br&gt;Data <del class="diffchange diffchange-inline">availability </del>&lt;br&gt;<del class="diffchange diffchange-inline">The intensity is plotted against the retention time for both chromatograms, demonstrating the 4F ADB presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. </del>LC-QTOF-MS <del class="diffchange diffchange-inline">Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) </del>in the <del class="diffchange diffchange-inline">Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine </del>and <del class="diffchange diffchange-inline">ADB-BUTINACA (Fig</del>. <del class="diffchange diffchange-inline">1). Because </del>the point-of-care <del class="diffchange diffchange-inline">DOA </del>test <del class="diffchange diffchange-inline">is generally not able to detect synthetic </del>recreational <del class="diffchange diffchange-inline">drug substances</del>, the <del class="diffchange diffchange-inline">liquid of the e-cigarette was thereafter screened using </del>liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) <del class="diffchange diffchange-inline">on </del>the <del class="diffchange diffchange-inline">Waters™ Xevo G3 QTOF MS system</del>. <del class="diffchange diffchange-inline">After eating </del>a <del class="diffchange diffchange-inline">light meal and drinking caffeinated sports drinks at </del>the <del class="diffchange diffchange-inline">ER</del>, <del class="diffchange diffchange-inline">the </del>nausea <del class="diffchange diffchange-inline">complaints of the patient were reduced and the patient was discharged hom&lt;br&gt;&lt;br&gt;The test apparatus for the locomotor activity test was designed to measure locomotor activity automatically using UV system (AM 1051, Benwick Electronics, Benwick</del>, <del class="diffchange diffchange-inline">UK) when experimental animals moved in the chambe&lt;br&gt;&lt;br&gt;&lt;br&gt;All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al.</del>, <del class="diffchange diffchange-inline">2017). Average horizontal activity counts/10 min as a function of time (10 min bins) </del>and <del class="diffchange diffchange-inline">dose</del>. <del class="diffchange diffchange-inline">Depressant effects of 1.33 mg/kg were observed within 10 min following administration </del>and <del class="diffchange diffchange-inline">peak depressant effects were [https://cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com/ 4F ADB] observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;In the present study</del>, <del class="diffchange diffchange-inline">we performed various methods based on animal behavioral </del>testing <del class="diffchange diffchange-inline">including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, </del>and <del class="diffchange diffchange-inline">water-maze test for learning/memory evaluation</del>. <del class="diffchange diffchange-inline">Known for its stability </del>and <del class="diffchange diffchange-inline">consistent composition, this compound is frequently utilized </del>by <del class="diffchange diffchange-inline">professionals seeking reliable materials for laboratory</del>-<del class="diffchange diffchange-inline">based analytical studies</del>. In this <del class="diffchange diffchange-inline">study</del>, <del class="diffchange diffchange-inline">histopathological evaluation </del>was <del class="diffchange diffchange-inline">performed </del>to <del class="diffchange diffchange-inline">confirm the possibility of neurotoxicity of the tested substances by hematoxylin and eosin staining method from collected brain samples. In </del>the <del class="diffchange diffchange-inline">present study, we evaluated the neurotoxicity of two </del>synthetic <del class="diffchange diffchange-inline">cannabinoids (JWH-081 and JWH</del>-<del class="diffchange diffchange-inline">210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, 1, 5 mg/kg). Selecting powder JWH-210 demands careful evaluation of purity, legality, and supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Acute kidney damage and even kidney failure have been reported following use of synthetic cannabinoids (Davidson, et al., 2017). One recent study has looked at other mechanisms of action in some of the older synthetic cannabinoids and reported that some produced varying amounts of activity at sites which are related </ins>to <ins class="diffchange diffchange-inline">cardiotoxicity and heart disease (Wiley et al., 2016)</ins>. It <ins class="diffchange diffchange-inline">is not known whether </ins>the <ins class="diffchange diffchange-inline">increased toxicity is due only to activation of CB1 cannabinoid receptors more strongly than Δ9-THC or whether these &quot;super-strength&quot; cannabinoids produce effects at other receptors</ins>. <ins class="diffchange diffchange-inline">A major cause of concern is </ins>that <ins class="diffchange diffchange-inline">some of the more recently seen synthetic cannabinoids are more likely to produce extremely toxic effects than </ins>the <ins class="diffchange diffchange-inline">older synthetics (Tai and Fantegrossi, 2017</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">In summary, JWH-210 Chemical Powder stands out as a high</ins>-<ins class="diffchange diffchange-inline">quality research compound designed for professionals who demand accuracy, consistency, and reliability</ins>. <ins class="diffchange diffchange-inline">This commitment to 5CLADBA quality makes it a trusted option for professionals who require dependable compounds </ins>for <ins class="diffchange diffchange-inline">their work. From sourcing raw materials to final packaging, every stage </ins>of the <ins class="diffchange diffchange-inline">process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;Key Features and Specifications to Evaluate &lt;br&gt;In case </ins>of <ins class="diffchange diffchange-inline">cannabis or Δ9-tetrahydrocannabinol, there are many [https://cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com</ins>/ <ins class="diffchange diffchange-inline">5CLADBA] previous studies regarding with their dependence potential and neurotoxicity </ins>(<ins class="diffchange diffchange-inline">Cororan, </ins>et al., <ins class="diffchange diffchange-inline">1974; Harris</ins>, <ins class="diffchange diffchange-inline">et al</ins>.<ins class="diffchange diffchange-inline">, 1974; Leite and Culini, 1974; Hutcheson, </ins>et al., <ins class="diffchange diffchange-inline">1998</ins>)<ins class="diffchange diffchange-inline">. After administering test substances once every other day for 10 days, brain samples of mice were collected, especially at nucleus accumbens and hippocampus regions. Drug was administered 5 times every other day</ins>, and the <ins class="diffchange diffchange-inline">first trial was performed 2 h after </ins>the <ins class="diffchange diffchange-inline">last administration</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;How to Choose Powder JWH-210 &lt;br&gt;This dual-use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks</ins>. <ins class="diffchange diffchange-inline">Forensic labs, public health researchers</ins>, <ins class="diffchange diffchange-inline">and customs officials use authentic samples like JWH</ins>-<ins class="diffchange diffchange-inline">210 to distinguish between legal and illegal </ins>compounds <ins class="diffchange diffchange-inline">in seized materials. For those seeking </ins>a <ins class="diffchange diffchange-inline">dependable compound for analytical purposes</ins>, <ins class="diffchange diffchange-inline">JWH</ins>-<ins class="diffchange diffchange-inline">210 Chemical Powder provides a trusted </ins>and <ins class="diffchange diffchange-inline">effective solution</ins>. <ins class="diffchange diffchange-inline">With its carefully controlled production process</ins>, <ins class="diffchange diffchange-inline">stable composition</ins>, <ins class="diffchange diffchange-inline">and secure packaging</ins>, <ins class="diffchange diffchange-inline">it remains </ins>a <ins class="diffchange diffchange-inline">valuable resource for laboratory-based researc</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and </ins>2 hr after the administration<ins class="diffchange diffchange-inline">, respectively</ins>. <ins class="diffchange diffchange-inline">After the first injection</ins>, <ins class="diffchange diffchange-inline">6 mice of the positive control group (</ins>methamphetamine<ins class="diffchange diffchange-inline">, 5 mg/kg, i.p.) </ins>showed <ins class="diffchange diffchange-inline">loss of traction, of which </ins>4 <ins class="diffchange diffchange-inline">showed tremor</ins>. <ins class="diffchange diffchange-inline">Most of </ins>the <ins class="diffchange diffchange-inline">abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine </ins>treated <ins class="diffchange diffchange-inline">animals after 2 hr of administration</ins>. <ins class="diffchange diffchange-inline">Brain samples were prepared from the mice after the last administration </ins>of <ins class="diffchange diffchange-inline">test substance</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">LC separates the urine or blood sample and QTOF-MS provides high-</ins>resolution <ins class="diffchange diffchange-inline">and accurate </ins>mass <ins class="diffchange diffchange-inline">measurements for precise identification and structural elucidation of compounds. The </ins>LC-QTOF-MS <ins class="diffchange diffchange-inline">method offers a more comprehensive and sensitive approach for drug </ins>detection<ins class="diffchange diffchange-inline">, covering hundreds </ins>of recreational drugs, including <ins class="diffchange diffchange-inline">NPS</ins>. <ins class="diffchange diffchange-inline">Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate </ins>the <ins class="diffchange diffchange-inline">flow rate </ins>of <ins class="diffchange diffchange-inline">air through </ins>the <ins class="diffchange diffchange-inline">e-cigarette and/or add a diluent </ins>. <ins class="diffchange diffchange-inline">Of all </ins>e-cigarette <ins class="diffchange diffchange-inline">users registered at this forum</ins>, <ins class="diffchange diffchange-inline">7.8 % vaped SCRAs . About 15 % </ins>of <ins class="diffchange diffchange-inline">individuals registered at forums for drug users such as erowid</ins>.<ins class="diffchange diffchange-inline">org who vaped cannabis have also vaped SRCAs</ins>. <ins class="diffchange diffchange-inline">SCRAs belong, together </ins>with <ins class="diffchange diffchange-inline">synthetic opioids</ins>, <ins class="diffchange diffchange-inline">cathinones</ins>, <ins class="diffchange diffchange-inline">amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed</ins>.&lt;br&gt;Data <ins class="diffchange diffchange-inline">availabili&lt;br&gt;&lt;br&gt;</ins>&lt;br&gt;LC-QTOF-MS <ins class="diffchange diffchange-inline">represents a significant advancement </ins>in the <ins class="diffchange diffchange-inline">field of drug detection, offering higher sensitivity, specificity, </ins>and <ins class="diffchange diffchange-inline">a broader spectrum of detectable substances</ins>. <ins class="diffchange diffchange-inline">Despite all negative results in </ins>the point-of-care test <ins class="diffchange diffchange-inline">for </ins>recreational <ins class="diffchange diffchange-inline">drugs</ins>, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) <ins class="diffchange diffchange-inline">analysis showed that the liquid of </ins>the <ins class="diffchange diffchange-inline">e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid</ins>. <ins class="diffchange diffchange-inline">We report </ins>a <ins class="diffchange diffchange-inline">27-year-old man who was admitted to </ins>the <ins class="diffchange diffchange-inline">emergency room because of sudden 5CLADBA headache</ins>, nausea, <ins class="diffchange diffchange-inline">vertigo</ins>, <ins class="diffchange diffchange-inline">red eyes </ins>and <ins class="diffchange diffchange-inline">palpitations</ins>. <ins class="diffchange diffchange-inline">Synthetic cannabinoids are gaining popularity globally </ins>and <ins class="diffchange diffchange-inline">detection is not commonly available</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Data availability </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">When clinical presentation and/or initial DOA testing results are inconclusive</ins>, <ins class="diffchange diffchange-inline">additional </ins>testing <ins class="diffchange diffchange-inline">with LC-QTOF-MS can be valuable </ins>and <ins class="diffchange diffchange-inline">is recommended</ins>. <ins class="diffchange diffchange-inline">SCRAs </ins>and <ins class="diffchange diffchange-inline">other NPS may not be detected </ins>by <ins class="diffchange diffchange-inline">point-of</ins>-<ins class="diffchange diffchange-inline">care DOA tests</ins>. In this <ins class="diffchange diffchange-inline">case</ins>, <ins class="diffchange diffchange-inline">the point-of-care DOA urine screening </ins>was <ins class="diffchange diffchange-inline">not able </ins>to <ins class="diffchange diffchange-inline">detect </ins>the synthetic <ins class="diffchange diffchange-inline">cannabinoid ADB</ins>-<ins class="diffchange diffchange-inline">BUTINAC</ins></div></td></tr> </table>

StarlaSaldana91 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=149001&oldid=prev 2026-05-28T19:07:25Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:07, 28 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">4. Drugs &lt;br&gt;In general, </del>the <del class="diffchange diffchange-inline">locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in </del>mice <del class="diffchange diffchange-inline">that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted </del>for <del class="diffchange diffchange-inline">the discriminative stimulus effects of Δ9-THC</del>. <del class="diffchange diffchange-inline">Subsequently, a one-way analysis of variance </del>was <del class="diffchange diffchange-inline">conducted on horizontal activity counts for </del>the <del class="diffchange diffchange-inline">30-</del>min <del class="diffchange diffchange-inline">period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests</del>. <del class="diffchange diffchange-inline">A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted </del>on <del class="diffchange diffchange-inline">horizontal activity counts/</del>10 min <del class="diffchange diffchange-inline">interval</del>. <del class="diffchange diffchange-inline">Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times </del>of <del class="diffchange diffchange-inline">peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Michael B Gatch </del>&lt;br&gt;<del class="diffchange diffchange-inline">Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. </del>Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in <del class="diffchange diffchange-inline">3 of 8 mice (data not shown)</del>. <del class="diffchange diffchange-inline">Substantial depressant effects </del>were <del class="diffchange diffchange-inline">observed within </del>the <del class="diffchange diffchange-inline">first 10 min, and maximal </del>depression <del class="diffchange diffchange-inline">was observed between 10–40 min and lasted up to 2</del>.<del class="diffchange diffchange-inline">5 to 3 h at </del>the <del class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com/ adb butinaca] highest dose tested (0</del>.<del class="diffchange diffchange-inline">5 </del>mg/kg<del class="diffchange diffchange-inline">).&lt;br&gt;Figure 1. &lt;br&gt;There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 </del>(<del class="diffchange diffchange-inline">Wiley </del>et al., <del class="diffchange diffchange-inline">2016</del>), <del class="diffchange diffchange-inline">and </del>a <del class="diffchange diffchange-inline">compound from the present study, 5F-MDMB-PINACA, </del>was <del class="diffchange diffchange-inline">found to activate midbrain dopamine neurons, but not serotonin neurons </del>(<del class="diffchange diffchange-inline">Asaoka </del>et al., <del class="diffchange diffchange-inline">2016</del>)<del class="diffchange diffchange-inline">. As previously mentioned</del>, <del class="diffchange diffchange-inline">all </del>of the <del class="diffchange diffchange-inline">compounds tested in the present study (MDMB</del>-<del class="diffchange diffchange-inline">PINACA</del>, <del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">CHMICA, MDMB-FUBINACA, ADB-FUBINACA</del>, and <del class="diffchange diffchange-inline">AMB</del>-<del class="diffchange diffchange-inline">FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these </del>compounds <del class="diffchange diffchange-inline">will produce Δ9</del>-<del class="diffchange diffchange-inline">THC-like </del>effects<del class="diffchange diffchange-inline">, including abuse liability</del>. <del class="diffchange diffchange-inline">Tremors were not observed following AMB</del>-<del class="diffchange diffchange-inline">FUBINACA during the drug discrimination study</del>, <del class="diffchange diffchange-inline">but the maximum dose tested was only 0.</del>1 <del class="diffchange diffchange-inline">mg/kg</del>, <del class="diffchange diffchange-inline">which is 10-fold lower </del>than <del class="diffchange diffchange-inline">the dose that produced tremors in the mic</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Moreover, genetic makeup, physiological conditions </del>(<del class="diffchange diffchange-inline">age, gender and ethnicity</del>), <del class="diffchange diffchange-inline">environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate </del>the <del class="diffchange diffchange-inline">metabolism </del>of <del class="diffchange diffchange-inline">drug</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert</del>-<del class="diffchange diffchange-inline">leucine </del>and <del class="diffchange diffchange-inline">indazole moieties remained unchanged, leading to the structure elucidation </del>of a <del class="diffchange diffchange-inline">hydroxy</del>-<del class="diffchange diffchange-inline">functional group at the 4</del>-<del class="diffchange diffchange-inline">position </del>of <del class="diffchange diffchange-inline">the butyl side chain by oxidative defluorination. The product ion m/z 336 </del>(<del class="diffchange diffchange-inline">loss of methyl ester moiety</del>) <del class="diffchange diffchange-inline">further confirmed </del>the <del class="diffchange diffchange-inline">presence </del>of <del class="diffchange diffchange-inline">dihydroxylated metabolites</del>. <del class="diffchange diffchange-inline">The precursor ion, m/z 364 (B14, B5/B6) had a loss </del>of <del class="diffchange diffchange-inline">2 Da </del>from <del class="diffchange diffchange-inline">m/z 366 indicated further dehydrogenation </del>of <del class="diffchange diffchange-inline">the ester hydrolysis plus monohydroxylated metabolites</del>. <del class="diffchange diffchange-inline">The presence </del>of <del class="diffchange diffchange-inline">the product ion m/z 320, likely formed from </del>a <del class="diffchange diffchange-inline">loss of carbon dioxide, indicated monohydroxylation at the tert</del>-<del class="diffchange diffchange-inline">leucine in B8 (m/z 219)</del>, <del class="diffchange diffchange-inline">butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion</del>, <del class="diffchange diffchange-inline">m/z 350 showed a loss </del>of <del class="diffchange diffchange-inline">14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Fig. 2. </del>&lt;br&gt;4F-<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">BINACA was hydrolysed via ester hydrolysis forming the 4F</del>-<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">BINACA ester hydrolysis metabolite </del>(<del class="diffchange diffchange-inline">B22</del>)<del class="diffchange diffchange-inline">. Data obtained from </del>the <del class="diffchange diffchange-inline">twenty urine samples were retrospectively analysed and processed using TraceFinder software based on </del>the <del class="diffchange diffchange-inline">identification criteria of mass errors less than ± 5 ppm for full </del>MS <del class="diffchange diffchange-inline">peaks and MS/MS peaks from </del>the <del class="diffchange diffchange-inline">theoretical mass </del>and <del class="diffchange diffchange-inline">matching of MS/MS spectra</del>. <del class="diffchange diffchange-inline">The mixture was vortex</del>-<del class="diffchange diffchange-inline">mixed and 500 µL </del>of <del class="diffchange diffchange-inline">this mixture and 500 µL </del>of <del class="diffchange diffchange-inline">methanol were loaded onto </del>the <del class="diffchange diffchange-inline">Clean Screen FASt® tube. After incubation, the mixture </del>was <del class="diffchange diffchange-inline">cooled at room temperature, and 150 µL </del>of <del class="diffchange diffchange-inline">purified water was added. High</del>-<del class="diffchange diffchange-inline">resolution </del>QTOF-MS <del class="diffchange diffchange-inline">data were acquired </del>on <del class="diffchange diffchange-inline">an Agilent 6510 Accurate Mass </del>QTOF <del class="diffchange diffchange-inline">mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive </del>and <del class="diffchange diffchange-inline">negative ion modes</del>, <del class="diffchange diffchange-inline">to determine accurate masses </del>of the <del class="diffchange diffchange-inline">metabolites. Chromatographic separation </del>was <del class="diffchange diffchange-inline">performed on an Agilent 1290 LC </del>system <del class="diffchange diffchange-inline">with a Poroshell 120 EC-C18 analytical column </del>(<del class="diffchange diffchange-inline">2.7 μm</del>, <del class="diffchange diffchange-inline">75 × 2.1 mm; Agilent Technologies</del>, <del class="diffchange diffchange-inline">Santa Clara</del>, <del class="diffchange diffchange-inline">CA, USA</del>)<del class="diffchange diffchange-inline">.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Fig. 1. </del>&lt;br&gt;<del class="diffchange diffchange-inline">Monitoring metabolism </del>of <del class="diffchange diffchange-inline">synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed </del>in <del class="diffchange diffchange-inline">cultured hepatoma cell line, fungus, adb butinaca liver microsomes and confirmed using urine samples The threshold </del>for <del class="diffchange diffchange-inline">fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL </del>(<del class="diffchange diffchange-inline">0</del>.<del class="diffchange diffchange-inline">37–4</del>.<del class="diffchange diffchange-inline">1 ng</del>/<del class="diffchange diffchange-inline">mL according to the reported cases</del>) of <del class="diffchange diffchange-inline">SCRA and </del>1.<del class="diffchange diffchange-inline">5–2</del>.<del class="diffchange diffchange-inline">5 g</del>/<del class="diffchange diffchange-inline">L of ethanol</del>. <del class="diffchange diffchange-inline">The reported cases and reviews </del>of the <del class="diffchange diffchange-inline">scientific literature suggest a possible synergistic effect between SCRAs and ethanol, because their combined use clearly increases their toxicity</del>. <del class="diffchange diffchange-inline">The victim died due </del>to <del class="diffchange diffchange-inline">severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30], but no data on high doses of ethanol are available. Given that THC and ethanol act on the same receptors, data on their simultaneous use may yield important insights in this regard</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Fungus C. elegans </del>&lt;br&gt;<del class="diffchange diffchange-inline">Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3</del>,<del class="diffchange diffchange-inline">3-dimethylbutanoate (4F-MDMB-BINACA</del>, <del class="diffchange diffchange-inline">4F</del>-<del class="diffchange diffchange-inline">MDMB-BUTINACA or 4F-ADB)</del>, <del class="diffchange diffchange-inline">found in numerous SCB product seizures, has been reported </del>by <del class="diffchange diffchange-inline">various law enforcement since 2018 </del>. <del class="diffchange diffchange-inline">However</del>, <del class="diffchange diffchange-inline">most </del>of the <del class="diffchange diffchange-inline">SCBs are full agonists at CB1 </del>and <del class="diffchange diffchange-inline">CB2 receptors</del>, <del class="diffchange diffchange-inline">having a higher risk </del>of <del class="diffchange diffchange-inline">undesirable side effects when compared to THC which is a partial agonist . Synthetic </del>cannabinoids (<del class="diffchange diffchange-inline">SCBs</del>) <del class="diffchange diffchange-inline">are agonists at cannabinoid receptor type </del>1 <del class="diffchange diffchange-inline">(CB1</del>) and <del class="diffchange diffchange-inline">type 2 (CB2)</del>, <del class="diffchange diffchange-inline">where they elicit their main effect</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">The same procedure was then applied to </ins>the mice <ins class="diffchange diffchange-inline">once every day </ins>for <ins class="diffchange diffchange-inline">5 days</ins>. <ins class="diffchange diffchange-inline">It </ins>was <ins class="diffchange diffchange-inline">considered as coordination disturbance when mice fell from </ins>the <ins class="diffchange diffchange-inline">test apparatus within 2 </ins>min. <ins class="diffchange diffchange-inline">Mice that remained their position </ins>on <ins class="diffchange diffchange-inline">the running apparatus at </ins>10 <ins class="diffchange diffchange-inline">rpm for at least 2 </ins>min <ins class="diffchange diffchange-inline">were selected for further evaluation</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;Table </ins>of <ins class="diffchange diffchange-inline">Conten&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;Tremors were observed <ins class="diffchange diffchange-inline">in mice </ins>30 minutes following 1 mg/kg AMB-FUBINACA in <ins class="diffchange diffchange-inline">the present study</ins>. <ins class="diffchange diffchange-inline">Pretreatment times and dose ranges for the drug discrimination assay </ins>were <ins class="diffchange diffchange-inline">selected based on </ins>the <ins class="diffchange diffchange-inline">time of peak </ins>depression <ins class="diffchange diffchange-inline">in the locomotor activity assay in mice</ins>. <ins class="diffchange diffchange-inline">Average potency of </ins>the <ins class="diffchange diffchange-inline">discriminative stimulus effects of early compounds was 0</ins>.<ins class="diffchange diffchange-inline">81±0</ins>.<ins class="diffchange diffchange-inline">17 </ins>mg/kg (<ins class="diffchange diffchange-inline">Gatch </ins>et al., <ins class="diffchange diffchange-inline">2014</ins>), <ins class="diffchange diffchange-inline">whereas the potency of </ins>a <ins class="diffchange diffchange-inline">recent set </ins>was <ins class="diffchange diffchange-inline">0.09±0.03 mg/kg </ins>(<ins class="diffchange diffchange-inline">Gatch </ins>et al., <ins class="diffchange diffchange-inline">2018</ins>), <ins class="diffchange diffchange-inline">and the potency </ins>of the <ins class="diffchange diffchange-inline">current set is 0.05±0.01 mg/kg. Short</ins>-<ins class="diffchange diffchange-inline">onset</ins>, <ins class="diffchange diffchange-inline">short</ins>-<ins class="diffchange diffchange-inline">acting compounds have a greater abuse liability</ins>, and <ins class="diffchange diffchange-inline">long</ins>-<ins class="diffchange diffchange-inline">acting </ins>compounds <ins class="diffchange diffchange-inline">pose problems of long</ins>-<ins class="diffchange diffchange-inline">acting adverse </ins>effects <ins class="diffchange diffchange-inline">and interactions with other drugs</ins>. <ins class="diffchange diffchange-inline">The duration of action of the synthetic cannabinoids tested using the 8</ins>-<ins class="diffchange diffchange-inline">h protocol have varied widely</ins>, <ins class="diffchange diffchange-inline">with some producing a duration of action no longer than </ins>1 <ins class="diffchange diffchange-inline">h, others producing a duration of action between 1–2 h</ins>, <ins class="diffchange diffchange-inline">and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent </ins>than <ins class="diffchange diffchange-inline">earlier compound&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Such decrease remained 2 hr after the administration </ins>(<ins class="diffchange diffchange-inline">Table 4</ins>)<ins class="diffchange diffchange-inline">. In locomotor activity</ins>, <ins class="diffchange diffchange-inline">methamphetamine treated group showed approximately 4.2 times increase compared to </ins>the <ins class="diffchange diffchange-inline">negative control treated group. Change </ins>of <ins class="diffchange diffchange-inline">body weight following the treatments with JWH-081 and JWH-210 in mic</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">High resolution mass spectrometry such as LC-QTOF</ins>-<ins class="diffchange diffchange-inline">MS allows the detection </ins>and <ins class="diffchange diffchange-inline">identification </ins>of a <ins class="diffchange diffchange-inline">broad spectrum of recreational drugs, including new psychoactive substances. A point</ins>-<ins class="diffchange diffchange-inline">of</ins>-<ins class="diffchange diffchange-inline">care drugs </ins>of <ins class="diffchange diffchange-inline">abuse </ins>(<ins class="diffchange diffchange-inline">DOA</ins>) <ins class="diffchange diffchange-inline">test was initially performed on </ins>the <ins class="diffchange diffchange-inline">urine </ins>of <ins class="diffchange diffchange-inline">the patient</ins>. <ins class="diffchange diffchange-inline">He confirmed drinking 750 ml energy drink without any further consumption </ins>of <ins class="diffchange diffchange-inline">food and using an e-cigarette </ins>from <ins class="diffchange diffchange-inline">Gaziantep, Turkey 10 seconds before the onset </ins>of <ins class="diffchange diffchange-inline">his first symptoms</ins>. <ins class="diffchange diffchange-inline">He usually smokes a pack </ins>of <ins class="diffchange diffchange-inline">cigarettes </ins>a <ins class="diffchange diffchange-inline">day and sometimes smokes e-cigarettes. Combined with non</ins>-<ins class="diffchange diffchange-inline">specific</ins>, <ins class="diffchange diffchange-inline">transient symptoms</ins>, <ins class="diffchange diffchange-inline">clinical recognition </ins>of <ins class="diffchange diffchange-inline">SCRA intoxication is challenging </ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Data availability </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">The intensity is plotted against the retention time for both chromatograms, demonstrating the </ins>4F <ins class="diffchange diffchange-inline">ADB presence and elution profiles of nicotine and ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA in the analysed vape liquid sample. LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS Chromatograms of Nicotine (Top) and ADB</ins>-<ins class="diffchange diffchange-inline">BUTINACA </ins>(<ins class="diffchange diffchange-inline">Bottom</ins>) <ins class="diffchange diffchange-inline">in </ins>the <ins class="diffchange diffchange-inline">Vape Liquid used by </ins>the <ins class="diffchange diffchange-inline">patient. The LC-QTOF-</ins>MS <ins class="diffchange diffchange-inline">analysis showed that </ins>the <ins class="diffchange diffchange-inline">e-liquid contained nicotine </ins>and <ins class="diffchange diffchange-inline">ADB-BUTINACA (Fig. 1)</ins>. <ins class="diffchange diffchange-inline">Because the point</ins>-of<ins class="diffchange diffchange-inline">-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid </ins>of the <ins class="diffchange diffchange-inline">e-cigarette </ins>was <ins class="diffchange diffchange-inline">thereafter screened using liquid chromatography-quadrupole time-</ins>of-<ins class="diffchange diffchange-inline">flight mass spectrometry (LC-</ins>QTOF-MS<ins class="diffchange diffchange-inline">) </ins>on <ins class="diffchange diffchange-inline">the Waters™ Xevo G3 </ins>QTOF <ins class="diffchange diffchange-inline">MS system. After eating a light meal </ins>and <ins class="diffchange diffchange-inline">drinking caffeinated sports drinks at the ER</ins>, <ins class="diffchange diffchange-inline">the nausea complaints </ins>of the <ins class="diffchange diffchange-inline">patient were reduced and the patient was discharged hom&lt;br&gt;&lt;br&gt;The test apparatus for the locomotor activity test </ins>was <ins class="diffchange diffchange-inline">designed to measure locomotor activity automatically using UV </ins>system (<ins class="diffchange diffchange-inline">AM 1051</ins>, <ins class="diffchange diffchange-inline">Benwick Electronics</ins>, <ins class="diffchange diffchange-inline">Benwick</ins>, <ins class="diffchange diffchange-inline">UK</ins>) <ins class="diffchange diffchange-inline">when experimental animals moved in the chambe&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">All </ins>of <ins class="diffchange diffchange-inline">the compounds tested </ins>in <ins class="diffchange diffchange-inline">the present study depressed locomotor activity as is typical </ins>for <ins class="diffchange diffchange-inline">other synthetic cannabinoids </ins>(<ins class="diffchange diffchange-inline">see review by Wiley et al</ins>.<ins class="diffchange diffchange-inline">, 2017)</ins>. <ins class="diffchange diffchange-inline">Average horizontal activity counts</ins>/<ins class="diffchange diffchange-inline">10 min as a function of time (10 min bins</ins>) <ins class="diffchange diffchange-inline">and dose. Depressant effects </ins>of 1.<ins class="diffchange diffchange-inline">33 mg/kg were observed within 10 min following administration and peak depressant effects were [https://cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com</ins>/ <ins class="diffchange diffchange-inline">4F ADB] observed between 0–30 min</ins>. <ins class="diffchange diffchange-inline">Duration </ins>of the <ins class="diffchange diffchange-inline">locomotor depression increased over dose from 30 min following 0</ins>.<ins class="diffchange diffchange-inline">1 mg/kg </ins>to <ins class="diffchange diffchange-inline">2</ins>.<ins class="diffchange diffchange-inline">5 h following 1 mg/k&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">In the present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test</ins>, <ins class="diffchange diffchange-inline">locomotor activity test for motor function evaluation</ins>, <ins class="diffchange diffchange-inline">and water</ins>-<ins class="diffchange diffchange-inline">maze test for learning/memory evaluation. Known for its stability and consistent composition</ins>, <ins class="diffchange diffchange-inline">this compound is frequently utilized </ins>by <ins class="diffchange diffchange-inline">professionals seeking reliable materials for laboratory-based analytical studies</ins>. <ins class="diffchange diffchange-inline">In this study</ins>, <ins class="diffchange diffchange-inline">histopathological evaluation was performed to confirm the possibility of neurotoxicity </ins>of the <ins class="diffchange diffchange-inline">tested substances by hematoxylin </ins>and <ins class="diffchange diffchange-inline">eosin staining method from collected brain samples. In the present study</ins>, <ins class="diffchange diffchange-inline">we evaluated the neurotoxicity </ins>of <ins class="diffchange diffchange-inline">two synthetic </ins>cannabinoids (<ins class="diffchange diffchange-inline">JWH-081 and JWH-210</ins>) <ins class="diffchange diffchange-inline">through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, </ins>1<ins class="diffchange diffchange-inline">, 5 mg/kg</ins>)<ins class="diffchange diffchange-inline">. Selecting powder JWH-210 demands careful evaluation of purity, legality, </ins>and <ins class="diffchange diffchange-inline">supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity</ins>, <ins class="diffchange diffchange-inline">and vendor complianc</ins></div></td></tr> <!-- diff cache key my_wiki:diff::1.12:old-148774:rev-149001 --> </table>

StarlaSaldana91 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=148774&oldid=prev 2026-05-27T03:43:10Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 03:43, 27 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to https://cannabinoidsrc4f-adb.com/ quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Key Features </del>and <del class="diffchange diffchange-inline">Specifications to Evaluate &lt;br&gt;In case of cannabis or Δ9-tetrahydrocannabinol</del>, <del class="diffchange diffchange-inline">there are many https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb.com/ previous studies regarding with their dependence potential and neurotoxicity </del>(<del class="diffchange diffchange-inline">Cororan, </del>et al., <del class="diffchange diffchange-inline">1974; Harris</del>, <del class="diffchange diffchange-inline">et al., 1974; Leite </del>and <del class="diffchange diffchange-inline">Culini, 1974; Hutcheson, </del>et al., <del class="diffchange diffchange-inline">1998</del>). <del class="diffchange diffchange-inline">After administering test substances once every other day for 10 days, brain samples </del>of <del class="diffchange diffchange-inline">mice were collected, especially at nucleus accumbens and hippocampus regions. Drug was administered 5 times every other day, and </del>the <del class="diffchange diffchange-inline">first trial was performed 2 h after </del>the <del class="diffchange diffchange-inline">last administration.&lt;br&gt;How to Choose Powder JWH-210 &lt;br&gt;This dual-use nature underscores </del>the <del class="diffchange diffchange-inline">importance </del>of <del class="diffchange diffchange-inline">responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH</del>-<del class="diffchange diffchange-inline">210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution</del>. <del class="diffchange diffchange-inline">With its carefully controlled production process</del>, <del class="diffchange diffchange-inline">stable composition, and secure packaging, it remains </del>a <del class="diffchange diffchange-inline">valuable resource for laboratory-based research.&lt;br&gt;Is JWH</del>-<del class="diffchange diffchange-inline">210 Legal? &lt;br&gt;To evaluate whether the changes </del>of <del class="diffchange diffchange-inline">coordinative functions by CNS damages were due to test substances, rota-rod test </del>was <del class="diffchange diffchange-inline">performed using Rota</del>-<del class="diffchange diffchange-inline">rod apparatus (Daejong</del>, <del class="diffchange diffchange-inline">Seoul, Korea). The test apparatus </del>for the <del class="diffchange diffchange-inline">locomotor activity test was designed to measure locomotor activity automatically </del>using <del class="diffchange diffchange-inline">UV system (AM 1051, Benwick Electronics, Benwick, UK) when experimental animals moved in the chamber. In both </del>tests<del class="diffchange diffchange-inline">, a group of mice were treated with negative control (vehicle, 1 mg/kg, i</del>.<del class="diffchange diffchange-inline">p.), positive control (methamphetamine, 1 mg/kg, i.p.), or one of the three doses </del>of <del class="diffchange diffchange-inline">test substances (0.1</del>, <del class="diffchange diffchange-inline">1</del>, <del class="diffchange diffchange-inline">5 mg</del>/<del class="diffchange diffchange-inline">kg, i</del>.<del class="diffchange diffchange-inline">p.) once every other day </del>for <del class="diffchange diffchange-inline">10 day&lt;br&gt;&lt;br&gt;&lt;br&gt;Synthetic cannabinoids have consistently been shown to produce discriminative stimulus </del>effects <del class="diffchange diffchange-inline">similar </del>to <del class="diffchange diffchange-inline">those https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb.com/ </del>of <del class="diffchange diffchange-inline">Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al</del>.<del class="diffchange diffchange-inline">, 2018). The </del>chemical structures <del class="diffchange diffchange-inline">of the recent </del>synthetic cannabinoids <del class="diffchange diffchange-inline">are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are </del>known to have substantial abuse liability <del class="diffchange diffchange-inline">(Fig. 1). All 5 compounds decreased locomotor activity </del>and <del class="diffchange diffchange-inline">produced discriminative stimulus effects similar to those of Δ9-THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk in human recreational users</del>.&lt;br&gt;Michael B Gatch &lt;br&gt;<del class="diffchange diffchange-inline">Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. </del>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). Figure 1 <del class="diffchange diffchange-inline">shows average horizontal activity counts/10 min as a function </del>of <del class="diffchange diffchange-inline">time </del>(<del class="diffchange diffchange-inline">0–4 h</del>) and <del class="diffchange diffchange-inline">dose of Δ9-TH&lt;br&gt;&lt;br&gt;</del>5F-MDMB-PINACA (<del class="diffchange diffchange-inline">also known as 5F-ADB</del>, <del class="diffchange diffchange-inline">5F-ADB</del>-PINACA<del class="diffchange diffchange-inline">)</del>, MDMB-<del class="diffchange diffchange-inline">CHIMICA</del>, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (<del class="diffchange diffchange-inline">also known as FUB</del>-AMB<del class="diffchange diffchange-inline">, MMB</del>-FUBINACA<del class="diffchange diffchange-inline">) were </del>tested <del class="diffchange diffchange-inline">for </del>in <del class="diffchange diffchange-inline">vivo cannabinoid-like effects to assess their abuse liabilit</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">These synthetic cannabinoids act [https:</del>//<del class="diffchange diffchange-inline">cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com</del>/ <del class="diffchange diffchange-inline">https:</del>//<del class="diffchange diffchange-inline">cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com</del>/<del class="diffchange diffchange-inline">] directly </del>at <del class="diffchange diffchange-inline">cannabinoid CB1 and CB2 receptors as does Δ9</del>-<del class="diffchange diffchange-inline">tetrahydrocannabinol </del>(<del class="diffchange diffchange-inline">Δ9-THC</del>) <del class="diffchange diffchange-inline">found </del>in <del class="diffchange diffchange-inline">marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity </del>(<del class="diffchange diffchange-inline">Fantegrossi et al., 2014</del>)<del class="diffchange diffchange-inline">. Discriminative stimulus effects were tested </del>in <del class="diffchange diffchange-inline">rats trained to discriminate Δ9-tetrahydrocannabinol </del>(<del class="diffchange diffchange-inline">3 mg</del>/<del class="diffchange diffchange-inline">kg</del>, <del class="diffchange diffchange-inline">30</del>-<del class="diffchange diffchange-inline">min pretreatment)</del>. <del class="diffchange diffchange-inline">5F</del>-MDMB-<del class="diffchange diffchange-inline">PINACA </del>(<del class="diffchange diffchange-inline">also known as 5F</del>-<del class="diffchange diffchange-inline">ADB</del>, <del class="diffchange diffchange-inline">5F</del>-<del class="diffchange diffchange-inline">ADB</del>-<del class="diffchange diffchange-inline">PINACA</del>), <del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">CHIMICA</del>, <del class="diffchange diffchange-inline">MDMB-FUBINACA</del>, <del class="diffchange diffchange-inline">ADB-FUBINACA</del>, <del class="diffchange diffchange-inline">and AMB-FUBINACA (also known as FUB-AMB</del>, <del class="diffchange diffchange-inline">MMB-FUBINACA</del>) <del class="diffchange diffchange-inline">were tested for in vivo cannabinoid-like effects to assess their abuse liabilit</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Briefly, the FOB test was comprised </del>of <del class="diffchange diffchange-inline">several behavioral changes including catalepsy</del>, <del class="diffchange diffchange-inline">traction, tremor, convulsion, exopthalmos, piloerection, salivation, lacrimation, diarrhea, skin coloration, pinna reflex, righting reflex</del>, and <del class="diffchange diffchange-inline">death. </del>The <del class="diffchange diffchange-inline">FOB test was performed using published procedures </del>(<del class="diffchange diffchange-inline">Moser et al</del>.<del class="diffchange diffchange-inline">, 1989</del>) <del class="diffchange diffchange-inline">with some modifications</del>. <del class="diffchange diffchange-inline">However</del>, because <del class="diffchange diffchange-inline">of </del>their <del class="diffchange diffchange-inline">subjective properties, it is necessary </del>to <del class="diffchange diffchange-inline">set up a more objective automated measurement to determine their neurotoxicity</del>. <del class="diffchange diffchange-inline">However</del>, <del class="diffchange diffchange-inline">there </del>are <del class="diffchange diffchange-inline">only a couple of anecdotal reports suspecting </del>the <del class="diffchange diffchange-inline">possibility of </del>their <del class="diffchange diffchange-inline">neurotoxicity with no scientific evidence </del>(<del class="diffchange diffchange-inline">Cohen et al</del>., <del class="diffchange diffchange-inline">2012; McGuinness </del>and <del class="diffchange diffchange-inline">Newell</del>, <del class="diffchange diffchange-inline">2012; Harris </del>and <del class="diffchange diffchange-inline">Brown</del>, <del class="diffchange diffchange-inline">2013; Hermanns et al., 2013</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">4</ins>. <ins class="diffchange diffchange-inline">Drugs </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">In general, the locomotor depressant </ins>and <ins class="diffchange diffchange-inline">discriminative stimulus effects have been observed at doses that do not produce adverse effects</ins>, <ins class="diffchange diffchange-inline">although tremors were observed upon handling in mice that received JWH</ins>-<ins class="diffchange diffchange-inline">210 </ins>(<ins class="diffchange diffchange-inline">Gatch </ins>et al., <ins class="diffchange diffchange-inline">2016)</ins>, and <ins class="diffchange diffchange-inline">5F-AMB produced sustained vocalization and convulsions in rats (Gatch </ins>et al., <ins class="diffchange diffchange-inline">2018</ins>). <ins class="diffchange diffchange-inline">All </ins>of the <ins class="diffchange diffchange-inline">synthetic cannabinoids tested in </ins>the <ins class="diffchange diffchange-inline">present study fully substituted for </ins>the <ins class="diffchange diffchange-inline">discriminative stimulus effects </ins>of <ins class="diffchange diffchange-inline">Δ9</ins>-<ins class="diffchange diffchange-inline">THC</ins>. <ins class="diffchange diffchange-inline">Subsequently</ins>, a <ins class="diffchange diffchange-inline">one</ins>-<ins class="diffchange diffchange-inline">way analysis </ins>of <ins class="diffchange diffchange-inline">variance </ins>was <ins class="diffchange diffchange-inline">conducted on horizontal activity counts for the 30</ins>-<ins class="diffchange diffchange-inline">min period of maximal effect</ins>, <ins class="diffchange diffchange-inline">and planned comparisons were conducted </ins>for <ins class="diffchange diffchange-inline">each dose against </ins>the <ins class="diffchange diffchange-inline">vehicle control </ins>using <ins class="diffchange diffchange-inline">single degree-of-freedom F </ins>tests. <ins class="diffchange diffchange-inline">A two-way analysis </ins>of <ins class="diffchange diffchange-inline">variance</ins>, <ins class="diffchange diffchange-inline">with dose as a between groups factor and time as a within subject factor</ins>, <ins class="diffchange diffchange-inline">was conducted on horizontal activity counts</ins>/<ins class="diffchange diffchange-inline">10 min interval</ins>. <ins class="diffchange diffchange-inline">Locomotor activity in mice was tested to screen </ins>for <ins class="diffchange diffchange-inline">locomotor depressant </ins>effects <ins class="diffchange diffchange-inline">and </ins>to <ins class="diffchange diffchange-inline">identify behaviorally</ins>-<ins class="diffchange diffchange-inline">active dose ranges and times </ins>of <ins class="diffchange diffchange-inline">peak effect</ins>. <ins class="diffchange diffchange-inline">Previous studies have demonstrated that these compounds have </ins>chemical structures <ins class="diffchange diffchange-inline">similar to </ins>synthetic cannabinoids known to have substantial abuse liability and <ins class="diffchange diffchange-inline">act at the CB1 receptor</ins>.&lt;br&gt;Michael B Gatch &lt;br&gt;Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the <ins class="diffchange diffchange-inline">[https://cannabinoidsrc4f-adb.com/ adb butinaca] </ins>highest dose tested (0.5 mg/kg).<ins class="diffchange diffchange-inline">&lt;br&gt;</ins>Figure 1<ins class="diffchange diffchange-inline">. &lt;br&gt;There is indication that at least some </ins>of <ins class="diffchange diffchange-inline">the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 </ins>(<ins class="diffchange diffchange-inline">Wiley et al., 2016</ins>)<ins class="diffchange diffchange-inline">, </ins>and <ins class="diffchange diffchange-inline">a compound from the present study, </ins>5F-MDMB-PINACA<ins class="diffchange diffchange-inline">, was found to activate midbrain dopamine neurons, but not serotonin neurons </ins>(<ins class="diffchange diffchange-inline">Asaoka et al., 2016). As previously mentioned</ins>, <ins class="diffchange diffchange-inline">all of the compounds tested in the present study (MDMB</ins>-PINACA, MDMB-<ins class="diffchange diffchange-inline">CHMICA</ins>, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA<ins class="diffchange diffchange-inline">) act as agonists at CB1 receptors </ins>(<ins class="diffchange diffchange-inline">Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC</ins>-<ins class="diffchange diffchange-inline">like effects, including abuse liability. Tremors were not observed following </ins>AMB-FUBINACA <ins class="diffchange diffchange-inline">during the drug discrimination study, but the maximum dose </ins>tested <ins class="diffchange diffchange-inline">was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors </ins>in <ins class="diffchange diffchange-inline">the mic&lt;br&gt;&lt;br&gt;Moreover, genetic makeup, physiological conditions (age, gender and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drug</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Product ions detected at m</ins>/<ins class="diffchange diffchange-inline">z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m</ins>/<ins class="diffchange diffchange-inline">z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites</ins>. <ins class="diffchange diffchange-inline">The precursor ion, m</ins>/<ins class="diffchange diffchange-inline">z 364 (B14, B5</ins>/<ins class="diffchange diffchange-inline">B6) had a loss of 2 Da from m</ins>/<ins class="diffchange diffchange-inline">z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites</ins>. <ins class="diffchange diffchange-inline">The presence of the product ion m</ins>/<ins class="diffchange diffchange-inline">z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation </ins>at <ins class="diffchange diffchange-inline">the tert</ins>-<ins class="diffchange diffchange-inline">leucine in B8 </ins>(<ins class="diffchange diffchange-inline">m/z 219</ins>)<ins class="diffchange diffchange-inline">, butyl side chain </ins>in <ins class="diffchange diffchange-inline">B9 </ins>(<ins class="diffchange diffchange-inline">m/z 145</ins>) <ins class="diffchange diffchange-inline">and indazole moiety </ins>in <ins class="diffchange diffchange-inline">B13 </ins>(<ins class="diffchange diffchange-inline">m</ins>/<ins class="diffchange diffchange-inline">z 161). The precursor ion</ins>, <ins class="diffchange diffchange-inline">m/z 350 showed a loss of 14 Da explaining the hydrolysis of methyl ester from 4F-MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA.&lt;br&gt;Fig. 2</ins>. <ins class="diffchange diffchange-inline">&lt;br&gt;4F-MDMB-BINACA was hydrolysed via ester hydrolysis forming the 4F</ins>-MDMB-<ins class="diffchange diffchange-inline">BINACA ester hydrolysis metabolite </ins>(<ins class="diffchange diffchange-inline">B22). Data obtained from the twenty urine samples were retrospectively analysed and processed using TraceFinder software based on the identification criteria of mass errors less than ± 5 ppm for full MS peaks and MS/MS peaks from the theoretical mass and matching of MS/MS spectra. The mixture was vortex</ins>-<ins class="diffchange diffchange-inline">mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto the Clean Screen FASt® tube. After incubation, the mixture was cooled at room temperature</ins>, <ins class="diffchange diffchange-inline">and 150 µL of purified water was added. High</ins>-<ins class="diffchange diffchange-inline">resolution QTOF</ins>-<ins class="diffchange diffchange-inline">MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI</ins>) <ins class="diffchange diffchange-inline">source operated in both positive and negative ion modes</ins>, <ins class="diffchange diffchange-inline">to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC</ins>-<ins class="diffchange diffchange-inline">C18 analytical column (2.7 μm</ins>, <ins class="diffchange diffchange-inline">75 × 2.1 mm; Agilent Technologies</ins>, <ins class="diffchange diffchange-inline">Santa Clara</ins>, <ins class="diffchange diffchange-inline">CA</ins>, <ins class="diffchange diffchange-inline">USA</ins>)<ins class="diffchange diffchange-inline">.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Fig. 1. </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Monitoring metabolism </ins>of <ins class="diffchange diffchange-inline">synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line</ins>, <ins class="diffchange diffchange-inline">fungus</ins>, <ins class="diffchange diffchange-inline">adb butinaca liver microsomes </ins>and <ins class="diffchange diffchange-inline">confirmed using urine samples </ins>The <ins class="diffchange diffchange-inline">threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL </ins>(<ins class="diffchange diffchange-inline">0.37–4</ins>.<ins class="diffchange diffchange-inline">1 ng/mL according to the reported cases</ins>) <ins class="diffchange diffchange-inline">of SCRA and 1.5–2.5 g/L of ethanol</ins>. <ins class="diffchange diffchange-inline">The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol</ins>, because their <ins class="diffchange diffchange-inline">combined use clearly increases their toxicity. The victim died due </ins>to <ins class="diffchange diffchange-inline">severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission </ins>. <ins class="diffchange diffchange-inline">Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30]</ins>, <ins class="diffchange diffchange-inline">but no data on high doses of ethanol </ins>are <ins class="diffchange diffchange-inline">available. Given that THC and ethanol act on </ins>the <ins class="diffchange diffchange-inline">same receptors, data on </ins>their <ins class="diffchange diffchange-inline">simultaneous use may yield important insights in this regard.&lt;br&gt;Fungus C. elegans &lt;br&gt;Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate </ins>(<ins class="diffchange diffchange-inline">4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4F-ADB), found in numerous SCB product seizures, has been reported by various law enforcement since 2018 </ins>. <ins class="diffchange diffchange-inline">However</ins>, <ins class="diffchange diffchange-inline">most of the SCBs are full agonists at CB1 </ins>and <ins class="diffchange diffchange-inline">CB2 receptors</ins>, <ins class="diffchange diffchange-inline">having a higher risk of undesirable side effects when compared to THC which is a partial agonist . Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type 1 (CB1) </ins>and <ins class="diffchange diffchange-inline">type 2 (CB2)</ins>, <ins class="diffchange diffchange-inline">where they elicit their main effect</ins></div></td></tr> <!-- diff cache key my_wiki:diff::1.12:old-148771:rev-148774 --> </table>

RoslynGibson2 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=148771&oldid=prev 2026-05-27T03:41:47Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 03:41, 27 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Moreover, genetic makeup, physiological conditions (age, gender and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drug&lt;br&gt;&lt;br&gt;Because response suppression may compromise stimulus control, rats failing to complete at least ten responses during the test session were excluded from the analysis of the discriminative stimulus effects of that dose of test compoun&lt;br&gt;&lt;br&gt;&lt;br&gt;A limitation of this case report is that we did not have a urine sample available for additional NPS testing. Point-of-care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines and methadone. THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e-cigarettes, while crack cocaine is hard to vaporise. A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours .&lt;br&gt;Data availability &lt;br&gt;Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patien&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at [https://cannabinoidsrc4f-adb.com/ 5CLADBA] least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;</del>In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to <del class="diffchange diffchange-inline">5CLADBA </del>quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.&lt;br&gt;Key Features and Specifications to Evaluate &lt;br&gt;<del class="diffchange diffchange-inline">Higher prices often reflect rigorous quality control rather than markup alone</del>. <del class="diffchange diffchange-inline">This compound is appropriate only </del>for <del class="diffchange diffchange-inline">authorized professionals conducting lawful research or analysis</del>. <del class="diffchange diffchange-inline">For legitimate applications</del>, <del class="diffchange diffchange-inline">only fully characterized, independently tested JWH-210 5CLADBA should be considered</del>.&lt;br&gt;How to Choose Powder JWH-210 &lt;br&gt;This dual-use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based research.&lt;br&gt;Is JWH-210 Legal? &lt;br&gt;<del class="diffchange diffchange-inline">A total </del>of <del class="diffchange diffchange-inline">2 and 3 methamphetamine treated mice fell from the spinning </del>rod <del class="diffchange diffchange-inline">30 min and 2 hr after </del>the <del class="diffchange diffchange-inline">administration</del>, <del class="diffchange diffchange-inline">respectively</del>. <del class="diffchange diffchange-inline">After the first injection</del>, <del class="diffchange diffchange-inline">6 </del>mice <del class="diffchange diffchange-inline">of the </del>positive control <del class="diffchange diffchange-inline">group </del>(methamphetamine, <del class="diffchange diffchange-inline">5 </del>mg/kg, i.p.) <del class="diffchange diffchange-inline">showed loss of traction</del>, <del class="diffchange diffchange-inline">of which 4 showed tremor. Most </del>of the <del class="diffchange diffchange-inline">abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr </del>of <del class="diffchange diffchange-inline">administration</del>. <del class="diffchange diffchange-inline">Brain samples were prepared from the mice after the last administration of test substance</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Some mice showed abnormal behaviors </del>(<del class="diffchange diffchange-inline">catalepsy</del>, <del class="diffchange diffchange-inline">loss of traction</del>, <del class="diffchange diffchange-inline">convulsion</del>) <del class="diffchange diffchange-inline">right after </del>the <del class="diffchange diffchange-inline">administration </del>of the <del class="diffchange diffchange-inline">tested substances</del>. <del class="diffchange diffchange-inline">The </del>locomotor activity of the <del class="diffchange diffchange-inline">mice was measured </del>30 min <del class="diffchange diffchange-inline">and </del>2 <del class="diffchange diffchange-inline">hrs after </del>the <del class="diffchange diffchange-inline">last substance </del>administration. <del class="diffchange diffchange-inline">We also examined their neurotoxicity using brain samples through histopathological diagnose, especially </del>in the <del class="diffchange diffchange-inline">nucleus accumbens core region</del>. <del class="diffchange diffchange-inline">In histopathological analysis, neural cells of </del>the <del class="diffchange diffchange-inline">animals treated with the high </del>dose (5 mg/kg) of <del class="diffchange diffchange-inline">JWH</del>-<del class="diffchange diffchange-inline">081 or JWH</del>-<del class="diffchange diffchange-inline">210 showed distorted nuclei </del>and <del class="diffchange diffchange-inline">nucleus membranes </del>in the <del class="diffchange diffchange-inline">core shell </del>of <del class="diffchange diffchange-inline">nucleus accumbens</del>, <del class="diffchange diffchange-inline">suggesting </del>neurotoxicity.<del class="diffchange diffchange-inline">&lt;br&gt;Table </del>of <del class="diffchange diffchange-inline">Conten</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to <ins class="diffchange diffchange-inline">https://cannabinoidsrc4f-adb.com/ </ins>quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.&lt;br&gt;Key Features and Specifications to Evaluate &lt;br&gt;<ins class="diffchange diffchange-inline">In case of cannabis or Δ9-tetrahydrocannabinol, there are many https://cannabinoidsrc4f-adb.com/ previous studies regarding with their dependence potential and neurotoxicity (Cororan, et al., 1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998)</ins>. <ins class="diffchange diffchange-inline">After administering test substances once every other day </ins>for <ins class="diffchange diffchange-inline">10 days, brain samples of mice were collected, especially at nucleus accumbens and hippocampus regions</ins>. <ins class="diffchange diffchange-inline">Drug was administered 5 times every other day</ins>, <ins class="diffchange diffchange-inline">and the first trial was performed 2 h after the last administration</ins>.&lt;br&gt;How to Choose Powder JWH-210 &lt;br&gt;This dual-use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based research.&lt;br&gt;Is JWH-210 Legal? &lt;br&gt;<ins class="diffchange diffchange-inline">To evaluate whether the changes </ins>of <ins class="diffchange diffchange-inline">coordinative functions by CNS damages were due to test substances, rota-rod test was performed using Rota-</ins>rod <ins class="diffchange diffchange-inline">apparatus (Daejong, Seoul, Korea). The test apparatus for </ins>the <ins class="diffchange diffchange-inline">locomotor activity test was designed to measure locomotor activity automatically using UV system (AM 1051, Benwick Electronics, Benwick</ins>, <ins class="diffchange diffchange-inline">UK) when experimental animals moved in the chamber</ins>. <ins class="diffchange diffchange-inline">In both tests</ins>, <ins class="diffchange diffchange-inline">a group of </ins>mice <ins class="diffchange diffchange-inline">were treated with negative control (vehicle, 1 mg/kg, i.p.), </ins>positive control (methamphetamine, <ins class="diffchange diffchange-inline">1 </ins>mg/kg, i.p.), <ins class="diffchange diffchange-inline">or one </ins>of the <ins class="diffchange diffchange-inline">three doses </ins>of <ins class="diffchange diffchange-inline">test substances (0.1, 1, 5 mg/kg, i.p</ins>.<ins class="diffchange diffchange-inline">) once every other day for 10 day</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those https://cannabinoidsrc4f-adb.com/ of Δ9-THC </ins>(<ins class="diffchange diffchange-inline">Bannister and Connor, 2018)</ins>, <ins class="diffchange diffchange-inline">and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al.</ins>, <ins class="diffchange diffchange-inline">2018</ins>)<ins class="diffchange diffchange-inline">. The chemical structures of </ins>the <ins class="diffchange diffchange-inline">recent synthetic cannabinoids are unlike that </ins>of <ins class="diffchange diffchange-inline">Δ9-THC, but are largely based on </ins>the <ins class="diffchange diffchange-inline">structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1)</ins>. <ins class="diffchange diffchange-inline">All 5 compounds decreased </ins>locomotor activity <ins class="diffchange diffchange-inline">and produced discriminative stimulus effects similar to those of Δ9-THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk in human recreational users.&lt;br&gt;Michael B Gatch &lt;br&gt;Duration </ins>of the <ins class="diffchange diffchange-inline">locomotor depression increased over dose from </ins>30 min <ins class="diffchange diffchange-inline">following 0.1 mg/kg to </ins>2<ins class="diffchange diffchange-inline">.5 h following 1 mg/kg. Substantial depressant effects were observed within </ins>the <ins class="diffchange diffchange-inline">first 10 min, and maximal depression was observed between 0–30 min following </ins>administration. <ins class="diffchange diffchange-inline">Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA </ins>in <ins class="diffchange diffchange-inline">3 of 8 mice (data not shown). Substantial depressant effects were observed within </ins>the <ins class="diffchange diffchange-inline">first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2</ins>.<ins class="diffchange diffchange-inline">5 to 3 h at </ins>the <ins class="diffchange diffchange-inline">highest </ins>dose <ins class="diffchange diffchange-inline">tested </ins>(<ins class="diffchange diffchange-inline">0.</ins>5 mg/kg)<ins class="diffchange diffchange-inline">. Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h) and dose </ins>of <ins class="diffchange diffchange-inline">Δ9-TH&lt;br&gt;&lt;br&gt;5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;These synthetic cannabinoids act [https://cannabinoidsrc4f-adb.com/ https://cannabinoidsrc4f-adb.com/] directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB</ins>-<ins class="diffchange diffchange-inline">FUBINACA, ADB</ins>-<ins class="diffchange diffchange-inline">FUBINACA, </ins>and <ins class="diffchange diffchange-inline">AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for </ins>in <ins class="diffchange diffchange-inline">vivo cannabinoid-like effects to assess their abuse liabilit&lt;br&gt;&lt;br&gt;&lt;br&gt;Briefly, </ins>the <ins class="diffchange diffchange-inline">FOB test was comprised of several behavioral changes including catalepsy, traction, tremor, convulsion, exopthalmos, piloerection, salivation, lacrimation, diarrhea, skin coloration, pinna reflex, righting reflex, and death. The FOB test was performed using published procedures (Moser et al., 1989) with some modifications. However, because </ins>of <ins class="diffchange diffchange-inline">their subjective properties</ins>, <ins class="diffchange diffchange-inline">it is necessary to set up a more objective automated measurement to determine their </ins>neurotoxicity. <ins class="diffchange diffchange-inline">However, there are only a couple of anecdotal reports suspecting the possibility </ins>of <ins class="diffchange diffchange-inline">their neurotoxicity with no scientific evidence (Cohen et al., 2012; McGuinness and Newell, 2012; Harris and Brown, 2013; Hermanns et al., 2013</ins></div></td></tr> <!-- diff cache key my_wiki:diff::1.12:old-148752:rev-148771 --> </table>

ISZCindy643869 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=148752&oldid=prev 2026-05-27T03:33:15Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 03:33, 27 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Demographic </del>and <del class="diffchange diffchange-inline">clinical features are recorded </del>and <del class="diffchange diffchange-inline">blood </del>and<del class="diffchange diffchange-inline">/or </del>urine <del class="diffchange diffchange-inline">samples analysed </del>using <del class="diffchange diffchange-inline">high</del>-<del class="diffchange diffchange-inline">resolution accurate mass liquid chromatography</del>-<del class="diffchange diffchange-inline">mass spectrometry</del>. <del class="diffchange diffchange-inline">The authors declare </del>that <del class="diffchange diffchange-inline">they have no known competing financial interests or personal relationships that could have appeared </del>to <del class="diffchange diffchange-inline">influence </del>the <del class="diffchange diffchange-inline">work reported </del>in <del class="diffchange diffchange-inline">this paper</del>. <del class="diffchange diffchange-inline">Second</del>, <del class="diffchange diffchange-inline">we could not </del>[https://cannabinoidsrc4f-adb.com/ <del class="diffchange diffchange-inline">4F ADB</del>] <del class="diffchange diffchange-inline">retrieve further detailed information about </del>the <del class="diffchange diffchange-inline">e</del>-<del class="diffchange diffchange-inline">cigarette that was used by the patient such </del>as <del class="diffchange diffchange-inline">the label or the region of origin</del>. <del class="diffchange diffchange-inline">Whether </del>a <del class="diffchange diffchange-inline">recreational drug can be administered via vaping</del>, <del class="diffchange diffchange-inline">depends on whether the drug becomes volatile under the evaporation temperature </del>of the <del class="diffchange diffchange-inline">e</del>-<del class="diffchange diffchange-inline">cigarette</del>. <del class="diffchange diffchange-inline">Of these samples, 22 contained one </del>or <del class="diffchange diffchange-inline">more SCRAs</del>, <del class="diffchange diffchange-inline">THC was </del>only <del class="diffchange diffchange-inline">detected </del>in <del class="diffchange diffchange-inline">11 samples</del>, <del class="diffchange diffchange-inline">only one contained cannabidiol and 6 contained </del>a <del class="diffchange diffchange-inline">mixture of THC </del>and <del class="diffchange diffchange-inline">cannabidiol</del>. <del class="diffchange diffchange-inline">There is difficulty in finding the right information about the NPS</del>, <del class="diffchange diffchange-inline">defining their potency </del>and <del class="diffchange diffchange-inline">confirmation of their existence in e</del>-<del class="diffchange diffchange-inline">liquids or urine samples</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Data availabili</del>&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Furthermore, users </del>of <del class="diffchange diffchange-inline">these vapes </del>and <del class="diffchange diffchange-inline">alerting authorities may not notice </del>the <del class="diffchange diffchange-inline">addition </del>of <del class="diffchange diffchange-inline">recreational drugs to </del>the <del class="diffchange diffchange-inline">e-liquid as </del>the <del class="diffchange diffchange-inline">smell </del>of <del class="diffchange diffchange-inline">recreational drugs is lost during vaping due to </del>the <del class="diffchange diffchange-inline">specific smell </del>of <del class="diffchange diffchange-inline">added flavours</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;Some mice showed abnormal behaviors (catalepsy, loss of traction, convulsion) right after the administration of the tested substances. The locomotor activity of the mice was measured 30 min and 2 hrs after the last substance administration. We also examined their neurotoxicity using brain samples through histopathological diagnose, especially in the nucleus accumbens core region. In histopathological analysis, neural cells of the animals treated with the high dose (5 mg/kg) of JWH-081 or JWH-210 showed distorted nuclei and nucleus membranes in the core shell of nucleus accumbens, suggesting neurotoxicity.&lt;br&gt;Table of Conten<del class="diffchange diffchange-inline">&lt;br&gt;&lt;br&gt;&lt;br&gt;A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to 4F ADB reinforcement. The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.&lt;br&gt;The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects, which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of the psychoactive effects in human users. The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. Since there is currently no robust measure of the reinforcing/rewarding effects of cannabinoids, drug discrimination is currently the best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;Because response suppression may compromise stimulus control, rats failing to complete at least ten responses during the test session were excluded from the analysis of the discriminative stimulus effects of that dose of test compoun&lt;br&gt;&lt;br&gt;&lt;br&gt;LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;&lt;br&gt;JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent and dependable, and this product delivers on both fronts. Whether used in small-scale experiments or larger research projects, the compound maintains its integrity under recommended storage conditions. This ensures ease of handling and precise measurement during laboratory use. Each batch undergoes detailed verification to ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study was supported by a grant (13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Kore</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Moreover, genetic makeup, physiological conditions (age, gender </ins>and <ins class="diffchange diffchange-inline">ethnicity), environmental influences (diet) </ins>and <ins class="diffchange diffchange-inline">pathological factors (liver diseases, diabetes, </ins>and <ins class="diffchange diffchange-inline">obesity) would further complicate the metabolism of drug&lt;br&gt;&lt;br&gt;Because response suppression may compromise stimulus control, rats failing to complete at least ten responses during the test session were excluded from the analysis of the discriminative stimulus effects of that dose of test compoun&lt;br&gt;&lt;br&gt;&lt;br&gt;A limitation of this case report is that we did not have a </ins>urine <ins class="diffchange diffchange-inline">sample available for additional NPS testing. Point-of-care DOA tests </ins>using <ins class="diffchange diffchange-inline">urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines and methadone. THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma</ins>-<ins class="diffchange diffchange-inline">hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e</ins>-<ins class="diffchange diffchange-inline">cigarettes, while crack cocaine is hard to vaporise</ins>. <ins class="diffchange diffchange-inline">A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed </ins>that <ins class="diffchange diffchange-inline">45 % of the patients who present at the ER after an intoxication due </ins>to <ins class="diffchange diffchange-inline">SCRA smoking recovered within 24 hours .&lt;br&gt;Data availability &lt;br&gt;Moreover, a study conducted in </ins>the <ins class="diffchange diffchange-inline">United Kingdom investigated components of e-liquids </ins>in <ins class="diffchange diffchange-inline">112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA</ins>. <ins class="diffchange diffchange-inline">Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines</ins>, <ins class="diffchange diffchange-inline">cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patien&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at </ins>[https://cannabinoidsrc4f-adb.com/ <ins class="diffchange diffchange-inline">5CLADBA</ins>] <ins class="diffchange diffchange-inline">least three rats completed the first fixed ratio, whereas all rats are shown for </ins>the <ins class="diffchange diffchange-inline">response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;In summary, JWH</ins>-<ins class="diffchange diffchange-inline">210 Chemical Powder stands out </ins>as <ins class="diffchange diffchange-inline">a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability</ins>. <ins class="diffchange diffchange-inline">This commitment to 5CLADBA quality makes it </ins>a <ins class="diffchange diffchange-inline">trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging</ins>, <ins class="diffchange diffchange-inline">every stage </ins>of the <ins class="diffchange diffchange-inline">process is monitored to ensure compliance with laboratory</ins>-<ins class="diffchange diffchange-inline">grade expectations</ins>. <ins class="diffchange diffchange-inline">This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.&lt;br&gt;Key Features and Specifications to Evaluate &lt;br&gt;Higher prices often reflect rigorous quality control rather than markup alone. This compound is appropriate only for authorized professionals conducting lawful research </ins>or <ins class="diffchange diffchange-inline">analysis. For legitimate applications</ins>, only <ins class="diffchange diffchange-inline">fully characterized, independently tested JWH-210 5CLADBA should be considered.&lt;br&gt;How to Choose Powder JWH-210 &lt;br&gt;This dual-use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds </ins>in <ins class="diffchange diffchange-inline">seized materials. For those seeking a dependable compound for analytical purposes</ins>, <ins class="diffchange diffchange-inline">JWH-210 Chemical Powder provides </ins>a <ins class="diffchange diffchange-inline">trusted </ins>and <ins class="diffchange diffchange-inline">effective solution</ins>. <ins class="diffchange diffchange-inline">With its carefully controlled production process, stable composition</ins>, and <ins class="diffchange diffchange-inline">secure packaging, it remains a valuable resource for laboratory</ins>-<ins class="diffchange diffchange-inline">based research</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Is JWH-210 Legal? </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">A total </ins>of <ins class="diffchange diffchange-inline">2 and 3 methamphetamine treated mice fell from the spinning rod 30 min </ins>and <ins class="diffchange diffchange-inline">2 hr after the administration, respectively. After </ins>the <ins class="diffchange diffchange-inline">first injection, 6 mice </ins>of the <ins class="diffchange diffchange-inline">positive control group (methamphetamine, 5 mg/kg, i.p.) showed loss of traction, of which 4 showed tremor. Most of </ins>the <ins class="diffchange diffchange-inline">abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr </ins>of <ins class="diffchange diffchange-inline">administration. Brain samples were prepared from the mice after </ins>the <ins class="diffchange diffchange-inline">last administration </ins>of <ins class="diffchange diffchange-inline">test substance</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;Some mice showed abnormal behaviors (catalepsy, loss of traction, convulsion) right after the administration of the tested substances. The locomotor activity of the mice was measured 30 min and 2 hrs after the last substance administration. We also examined their neurotoxicity using brain samples through histopathological diagnose, especially in the nucleus accumbens core region. In histopathological analysis, neural cells of the animals treated with the high dose (5 mg/kg) of JWH-081 or JWH-210 showed distorted nuclei and nucleus membranes in the core shell of nucleus accumbens, suggesting neurotoxicity.&lt;br&gt;Table of Conten</div></td></tr> <!-- diff cache key my_wiki:diff::1.12:old-148745:rev-148752 --> </table>

IanSalo763 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=148745&oldid=prev 2026-05-27T03:31:17Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 03:31, 27 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">A total of 2 </del>and <del class="diffchange diffchange-inline">3 methamphetamine treated mice fell from the spinning rod 30 min </del>and <del class="diffchange diffchange-inline">2 hr after </del>the <del class="diffchange diffchange-inline">administration</del>, <del class="diffchange diffchange-inline">respectively</del>. <del class="diffchange diffchange-inline">After </del>the <del class="diffchange diffchange-inline">first injection</del>, <del class="diffchange diffchange-inline">6 mice </del>of the <del class="diffchange diffchange-inline">positive control group (methamphetamine</del>, <del class="diffchange diffchange-inline">5 mg/kg</del>, <del class="diffchange diffchange-inline">i</del>.<del class="diffchange diffchange-inline">p</del>.<del class="diffchange diffchange-inline">) </del>showed loss of traction, of <del class="diffchange diffchange-inline">which 4 showed tremor</del>. <del class="diffchange diffchange-inline">Most </del>of the <del class="diffchange diffchange-inline">abnormalities were normalized in synthetic cannabinoid treated </del>mice <del class="diffchange diffchange-inline">although those abnormal behaviors remained in methamphetamine treated animals </del>after <del class="diffchange diffchange-inline">2 hr of </del>administration. <del class="diffchange diffchange-inline">Brain </del>samples <del class="diffchange diffchange-inline">were prepared from </del>the <del class="diffchange diffchange-inline">mice after </del>the <del class="diffchange diffchange-inline">last administration </del>of <del class="diffchange diffchange-inline">test substance</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to <del class="diffchange diffchange-inline">cannabinoidsrc4f-adb.com </del>reinforcement. The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.&lt;br&gt;The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects, which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of the psychoactive effects in human users. The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. Since there is currently no robust measure of the reinforcing/rewarding effects of cannabinoids, drug discrimination is currently the best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;This makes JWH-210 powder one of the most powerful compounds in its class</del>, <del class="diffchange diffchange-inline">often used in incense blends and research settings. Our commitment </del>to <del class="diffchange diffchange-inline">quality and customer satisfaction makes us </del>the <del class="diffchange diffchange-inline">best place for jwh 210 buy-whether you need it for research, incense blends, or other legal applications. For qualified professionals, investing in high-quality, verified material ensures accuracy, safety, and regulatory compliance. Prioritize vendors providing full analytical validation, transparent documentation, and compliance with international controls. Value is best assessed through consistency, verifiable purity, and regulatory compliance—not cost alon</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">The current study indicates that </del>the <del class="diffchange diffchange-inline">test compounds produce locomotor depression similar to that of Δ9</del>-<del class="diffchange diffchange-inline">THC, </del>and <del class="diffchange diffchange-inline">fully substitute </del>for <del class="diffchange diffchange-inline">the discriminative stimulus effects </del>of <del class="diffchange diffchange-inline">Δ9-THC</del>. <del class="diffchange diffchange-inline">In summary, these 5F</del>-<del class="diffchange diffchange-inline">MDMB</del>-<del class="diffchange diffchange-inline">PINACA</del>, <del class="diffchange diffchange-inline">MDMB-CHIMICA</del>, <del class="diffchange diffchange-inline">MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA have similar abuse liability as Δ9-tetrahydrocannabinol and should be controlled in a similar fashion</del>. <del class="diffchange diffchange-inline">Much of </del>the <del class="diffchange diffchange-inline">in vivo [https://cannabinoidsrc4f-adb.com/ cannabinoidsrc4f-adb.com] testing of </del>the <del class="diffchange diffchange-inline">synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like effects or like </del>the <del class="diffchange diffchange-inline">present study, focused on their abuse liability. There is indication that at least some </del>of the <del class="diffchange diffchange-inline">first</del>-<del class="diffchange diffchange-inline">generation synthetic cannabinoids act at receptors other than cannabinoid CB1 </del>and <del class="diffchange diffchange-inline">CB2 (Wiley et al</del>.<del class="diffchange diffchange-inline">, 2016), and a compound from the present study, 5F</del>-<del class="diffchange diffchange-inline">MDMB-PINACA, was found to activate midbrain dopamine neurons</del>, <del class="diffchange diffchange-inline">but not serotonin neurons (Asaoka et al</del>.<del class="diffchange diffchange-inline">, 2016&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects of individual doses were compared to the vehicle control value using a priori contrasts</del>. <del class="diffchange diffchange-inline">Response-rate data were analyzed by one-way repeated-measure analysis </del>of <del class="diffchange diffchange-inline">variance. Percent drug-appropriate responding was shown only if </del>at <del class="diffchange diffchange-inline">cannabinoidsrc4f-adb.com least three rats completed the first fixed ratio, whereas all rats are shown </del>for <del class="diffchange diffchange-inline">the response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;Morris water maze test was performed to evaluate the changes in learning and memory function</del>. <del class="diffchange diffchange-inline">Only a few case reports about the dangers of some synthetic cannabinoids due to neurotoxicity </del>have <del class="diffchange diffchange-inline">been published (Cohen et al</del>., <del class="diffchange diffchange-inline">2012; McGuinness et al.</del>, <del class="diffchange diffchange-inline">2012; Harris </del>and <del class="diffchange diffchange-inline">Brown, 2013; Hermanns et al., 2013). In addition, </del>the <del class="diffchange diffchange-inline">lack of information about neurotoxicity of synthetic cannabinoids could allow abusers consume those </del>substances <del class="diffchange diffchange-inline">undiscerningly. However, slight structural changes might cause biochemical properties including dependence liability and neurotoxicity. The substances used in the present study both possess naphthoylindole moiety as their parental structure. </del>(<del class="diffchange diffchange-inline">B</del>) <del class="diffchange diffchange-inline">The ratio of damaged cells containing pyknotic or condensed nuclei and low hematoxilin affinity to total cells were calculated in nucleus accumben</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">High resolution mass spectrometry such as LC</del>-<del class="diffchange diffchange-inline">QTOF-MS allows the detection </del>and <del class="diffchange diffchange-inline">identification of a broad spectrum of recreational drugs</del>, <del class="diffchange diffchange-inline">including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed </del>on <del class="diffchange diffchange-inline">the urine of the patient</del>. <del class="diffchange diffchange-inline">He confirmed drinking 750 ml energy drink without any further consumption of food and using an e</del>-<del class="diffchange diffchange-inline">cigarette from Gaziantep</del>, <del class="diffchange diffchange-inline">Turkey 10 seconds before </del>the <del class="diffchange diffchange-inline">onset of his first symptoms</del>. <del class="diffchange diffchange-inline">He usually smokes a pack </del>of <del class="diffchange diffchange-inline">cigarettes a day </del>and <del class="diffchange diffchange-inline">sometimes smokes e-cigarettes</del>. <del class="diffchange diffchange-inline">Combined with non-specific</del>, <del class="diffchange diffchange-inline">transient symptoms</del>, <del class="diffchange diffchange-inline">clinical recognition of SCRA intoxication is challenging .&lt;br&gt;Data availability &lt;br&gt;The intensity is plotted against the retention time </del>for <del class="diffchange diffchange-inline">both chromatograms, demonstrating the cannabinoidsrc4f-adb</del>.<del class="diffchange diffchange-inline">com presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used </del>by <del class="diffchange diffchange-inline">the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA </del>(<del class="diffchange diffchange-inline">Fig. 1</del>)<del class="diffchange diffchange-inline">. Because </del>the <del class="diffchange diffchange-inline">point-</del>of<del class="diffchange diffchange-inline">-care DOA test is generally not able to detect synthetic recreational drug substances</del>, <del class="diffchange diffchange-inline">the liquid </del>of <del class="diffchange diffchange-inline">the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal </del>and <del class="diffchange diffchange-inline">drinking caffeinated sports drinks at the ER</del>, <del class="diffchange diffchange-inline">the nausea complaints </del>of <del class="diffchange diffchange-inline">the patient were reduced and the patient was discharged hom</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Demographic and clinical features are recorded </ins>and <ins class="diffchange diffchange-inline">blood </ins>and<ins class="diffchange diffchange-inline">/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence </ins>the <ins class="diffchange diffchange-inline">work reported in this paper. Second</ins>, <ins class="diffchange diffchange-inline">we could not [https://cannabinoidsrc4f-adb</ins>.<ins class="diffchange diffchange-inline">com/ 4F ADB] retrieve further detailed information about the e-cigarette that was used by the patient such as </ins>the <ins class="diffchange diffchange-inline">label or the region of origin. Whether a recreational drug can be administered via vaping</ins>, <ins class="diffchange diffchange-inline">depends on whether the drug becomes volatile under the evaporation temperature </ins>of the <ins class="diffchange diffchange-inline">e-cigarette. Of these samples, 22 contained one or more SCRAs</ins>, <ins class="diffchange diffchange-inline">THC was only detected in 11 samples</ins>, <ins class="diffchange diffchange-inline">only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol</ins>. <ins class="diffchange diffchange-inline">There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples</ins>.<ins class="diffchange diffchange-inline">&lt;br&gt;Data availabili&lt;br&gt;&lt;br&gt;Furthermore, users of these vapes and alerting authorities may not notice the addition of recreational drugs to the e-liquid as the smell of recreational drugs is lost during vaping due to the specific smell of added flavours&lt;br&gt;&lt;br&gt;&lt;br&gt;Some mice </ins>showed <ins class="diffchange diffchange-inline">abnormal behaviors (catalepsy, </ins>loss of traction, <ins class="diffchange diffchange-inline">convulsion) right after the administration </ins>of <ins class="diffchange diffchange-inline">the tested substances</ins>. <ins class="diffchange diffchange-inline">The locomotor activity </ins>of the mice <ins class="diffchange diffchange-inline">was measured 30 min and 2 hrs </ins>after <ins class="diffchange diffchange-inline">the last substance </ins>administration. <ins class="diffchange diffchange-inline">We also examined their neurotoxicity using brain </ins>samples <ins class="diffchange diffchange-inline">through histopathological diagnose, especially in the nucleus accumbens core region. In histopathological analysis, neural cells of the animals treated with </ins>the <ins class="diffchange diffchange-inline">high dose (5 mg/kg) of JWH-081 or JWH-210 showed distorted nuclei and nucleus membranes in </ins>the <ins class="diffchange diffchange-inline">core shell of nucleus accumbens, suggesting neurotoxicity.&lt;br&gt;Table </ins>of <ins class="diffchange diffchange-inline">Conten</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;A 30-min period, beginning when maximal depression of locomotor activity first appeared as a function of dose, was used for analysis of dose-response data and calculation of ED50 values. During test sessions, both levers were active, such that ten consecutive responses on either lever led to <ins class="diffchange diffchange-inline">4F ADB </ins>reinforcement. The substitution tests occurred only if the rats had achieved 85% injection-appropriate responding on the two prior training sessions.&lt;br&gt;The locomotor activity assay was used to identify approximate time courses and dose ranges of psychoactive effects, which is useful for identifying parameters for drug discrimination experiments and are also predictive of the time course of the psychoactive effects in human users. The purpose of the present study was to assess the abuse liability of 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA. Since there is currently no robust measure of the reinforcing/rewarding effects of cannabinoids, drug discrimination is currently the best model for assessing abuse liability of cannabinoids. The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">Because response suppression may compromise stimulus control</ins>, <ins class="diffchange diffchange-inline">rats failing </ins>to <ins class="diffchange diffchange-inline">complete at least ten responses during the test session were excluded from the analysis of </ins>the <ins class="diffchange diffchange-inline">discriminative stimulus effects of that dose of test compoun</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">LC separates </ins>the <ins class="diffchange diffchange-inline">urine or blood sample and QTOF-MS provides high</ins>-<ins class="diffchange diffchange-inline">resolution </ins>and <ins class="diffchange diffchange-inline">accurate mass measurements </ins>for <ins class="diffchange diffchange-inline">precise identification and structural elucidation </ins>of <ins class="diffchange diffchange-inline">compounds</ins>. <ins class="diffchange diffchange-inline">The LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS method offers a more comprehensive and sensitive approach for drug detection</ins>, <ins class="diffchange diffchange-inline">covering hundreds of recreational drugs</ins>, <ins class="diffchange diffchange-inline">including NPS</ins>. <ins class="diffchange diffchange-inline">Besides increasing </ins>the <ins class="diffchange diffchange-inline">temperature to enlarge </ins>the <ins class="diffchange diffchange-inline">drug aerolisation and bioavailability, one can elevate </ins>the <ins class="diffchange diffchange-inline">flow rate </ins>of <ins class="diffchange diffchange-inline">air through </ins>the <ins class="diffchange diffchange-inline">e</ins>-<ins class="diffchange diffchange-inline">cigarette </ins>and<ins class="diffchange diffchange-inline">/or add a diluent </ins>. <ins class="diffchange diffchange-inline">Of all e</ins>-<ins class="diffchange diffchange-inline">cigarette users registered at this forum</ins>, <ins class="diffchange diffchange-inline">7</ins>.<ins class="diffchange diffchange-inline">8 % vaped SCRAs </ins>. <ins class="diffchange diffchange-inline">About 15 % </ins>of <ins class="diffchange diffchange-inline">individuals registered </ins>at <ins class="diffchange diffchange-inline">forums </ins>for <ins class="diffchange diffchange-inline">drug users such as erowid</ins>.<ins class="diffchange diffchange-inline">org who vaped cannabis </ins>have <ins class="diffchange diffchange-inline">also vaped SRCAs</ins>. <ins class="diffchange diffchange-inline">SCRAs belong</ins>, <ins class="diffchange diffchange-inline">together with synthetic opioids, cathinones</ins>, <ins class="diffchange diffchange-inline">amphetamines </ins>and <ins class="diffchange diffchange-inline">hallucinogens to </ins>the <ins class="diffchange diffchange-inline">new psychoactive </ins>substances (<ins class="diffchange diffchange-inline">NPS</ins>) <ins class="diffchange diffchange-inline">that are currently developed at high speed.&lt;br&gt;Data availabili</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">JWH</ins>-<ins class="diffchange diffchange-inline">210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent </ins>and <ins class="diffchange diffchange-inline">dependable</ins>, <ins class="diffchange diffchange-inline">and this product delivers </ins>on <ins class="diffchange diffchange-inline">both fronts</ins>. <ins class="diffchange diffchange-inline">Whether used in small</ins>-<ins class="diffchange diffchange-inline">scale experiments or larger research projects</ins>, the <ins class="diffchange diffchange-inline">compound maintains its integrity under recommended storage conditions</ins>. <ins class="diffchange diffchange-inline">This ensures ease </ins>of <ins class="diffchange diffchange-inline">handling </ins>and <ins class="diffchange diffchange-inline">precise measurement during laboratory use</ins>. <ins class="diffchange diffchange-inline">Each batch undergoes detailed verification to ensure purity, consistency</ins>, <ins class="diffchange diffchange-inline">and accuracy</ins>, <ins class="diffchange diffchange-inline">making it suitable </ins>for <ins class="diffchange diffchange-inline">controlled experimental environments</ins>. <ins class="diffchange diffchange-inline">This study was supported </ins>by <ins class="diffchange diffchange-inline">a grant </ins>(<ins class="diffchange diffchange-inline">13181MFDS654</ins>) <ins class="diffchange diffchange-inline">of </ins>the <ins class="diffchange diffchange-inline">National Institute </ins>of <ins class="diffchange diffchange-inline">Food and Drug Safety Evaluation</ins>, <ins class="diffchange diffchange-inline">Ministry </ins>of <ins class="diffchange diffchange-inline">Food </ins>and <ins class="diffchange diffchange-inline">Drug Safety</ins>, <ins class="diffchange diffchange-inline">Republic </ins>of <ins class="diffchange diffchange-inline">Kore</ins></div></td></tr> </table>

IanSalo763 https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=148644&oldid=prev 2026-05-26T07:08:05Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 07:08, 26 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">Due to the unknown toxicity </del>of <del class="diffchange diffchange-inline">newly emerging SCRAs, forensic assessments of cases involving these substances are challenging. According to </del>the <del class="diffchange diffchange-inline">reported cases </del>and <del class="diffchange diffchange-inline">reviews of </del>the <del class="diffchange diffchange-inline">scientific literature</del>, <del class="diffchange diffchange-inline">concurrent ethanol consumption should amplify </del>the <del class="diffchange diffchange-inline">toxicity of SCRAs. The concentration </del>of <del class="diffchange diffchange-inline">4F-MDMB-BINACA in </del>the <del class="diffchange diffchange-inline">postmortem blood was 2.50 and 2.34 ng/mL</del>, <del class="diffchange diffchange-inline">and blood alcohol concentration was 2.11 and 2.49 g</del>/<del class="diffchange diffchange-inline">L</del>, <del class="diffchange diffchange-inline">respectively</del>. <del class="diffchange diffchange-inline">Two fatal cases are reported caused by simultaneous consumption of 4F-MDMB-BINACA and ethanol.&lt;br&gt;Fig. 2</del>. <del class="diffchange diffchange-inline">&lt;br&gt;The precursor ion m/z 396 (B10, B12/B15</del>) <del class="diffchange diffchange-inline">was 32 Da higher than the parent drug</del>, <del class="diffchange diffchange-inline">4F-MDMB-BINACA, suggesting the addition </del>of <del class="diffchange diffchange-inline">two hydroxy groups</del>. <del class="diffchange diffchange-inline">All </del>the <del class="diffchange diffchange-inline">below explanations for transformations into metabolites are based on the data shown </del>in <del class="diffchange diffchange-inline">Fig. Metabolites were identified according to their precursor ions, product ions, and fragmentation patterns (Fig. 1). Traditional </del>in<del class="diffchange diffchange-inline">-vivo metabolism studies to generate human metabolites </del>of <del class="diffchange diffchange-inline">drugs relied heavily on the use of whole animal model systems, which are expensive, limited by drug </del>administration <del class="diffchange diffchange-inline">amount, influenced by species variation and faced by many ethical issues</del>. <del class="diffchange diffchange-inline">Eight in-vivo metabolites tentatively identified </del>were <del class="diffchange diffchange-inline">mainly products </del>of <del class="diffchange diffchange-inline">ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Fig. 1. </del>&lt;br&gt;<del class="diffchange diffchange-inline">Monitoring metabolism of synthetic cannabinoid 4F</del>-<del class="diffchange diffchange-inline">MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line</del>, <del class="diffchange diffchange-inline">fungus</del>, <del class="diffchange diffchange-inline">[https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb</del>.<del class="diffchange diffchange-inline">com/ </del>cannabinoidsrc4f-adb.com<del class="diffchange diffchange-inline">] liver microsomes and confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL (0.37–4.1 ng/mL according to the reported cases) of SCRA and 1.5–2.5 g/L of ethanol</del>. The <del class="diffchange diffchange-inline">reported cases and reviews of </del>the <del class="diffchange diffchange-inline">scientific literature suggest a possible synergistic effect between SCRAs and ethanol, because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi</del>-<del class="diffchange diffchange-inline">organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30], but no data on high doses of ethanol are available. Given that THC and ethanol act </del>on the <del class="diffchange diffchange-inline">same receptors, data on their simultaneous use may yield important insights in this regard</del>.&lt;br&gt;<del class="diffchange diffchange-inline">Fungus C. elegans &lt;br&gt;Concentrations </del>of <del class="diffchange diffchange-inline">4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL</del>, which are in <del class="diffchange diffchange-inline">line with published data</del>. <del class="diffchange diffchange-inline">Although </del>the <del class="diffchange diffchange-inline">lethal dose </del>of <del class="diffchange diffchange-inline">4F</del>-MDMB-<del class="diffchange diffchange-inline">BINACA is unknown</del>, <del class="diffchange diffchange-inline">its concentration in postmortem blood samples was found to range between 0.10 </del>and <del class="diffchange diffchange-inline">2</del>.<del class="diffchange diffchange-inline">90 ng</del>/<del class="diffchange diffchange-inline">mL . In SCRA-related cases in which the deceased suffered from heart disease</del>, the <del class="diffchange diffchange-inline">SCRA concentration in the postmortem blood was less than 1 ng/mL </del>. <del class="diffchange diffchange-inline">Concentrations of SCRAs in postmortem cases cover a wide range ; however</del>, <del class="diffchange diffchange-inline">some reports of survival have also been published—even at relatively </del>high <del class="diffchange diffchange-inline">blood SCRA concentrations [19</del>, <del class="diffchange diffchange-inline">20&lt;br&gt;&lt;br&gt; In</del>-<del class="diffchange diffchange-inline">vitro metabolism studies are generally used </del>to <del class="diffchange diffchange-inline">complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled </del>human <del class="diffchange diffchange-inline">liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;This makes JWH-210 powder one of the most powerful compounds in its class, often used in incense blends and research settings. Our commitment to quality and customer satisfaction makes us the best place for jwh 210 buy-whether you need it for research, incense blends, or other legal applications. For qualified professionals, investing in high-quality, verified material ensures accuracy, safety, and regulatory compliance. Prioritize vendors providing full analytical validation, transparent documentation, and compliance with international controls. Value is best assessed through consistency, verifiable purity, and regulatory compliance—not cost alon&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">In </del>the <del class="diffchange diffchange-inline">present study</del>, <del class="diffchange diffchange-inline">we performed various methods based on animal behavioral testing including FOB test </del>for <del class="diffchange diffchange-inline">general behavioral observation</del>, <del class="diffchange diffchange-inline">rotarod test</del>, <del class="diffchange diffchange-inline">locomotor activity test for motor function evaluation</del>, and <del class="diffchange diffchange-inline">water</del>-<del class="diffchange diffchange-inline">maze test for learning</del>/<del class="diffchange diffchange-inline">memory evaluation</del>. <del class="diffchange diffchange-inline">Known for its stability </del>and <del class="diffchange diffchange-inline">consistent composition</del>, <del class="diffchange diffchange-inline">this </del>compound <del class="diffchange diffchange-inline">is frequently utilized </del>by <del class="diffchange diffchange-inline">professionals seeking reliable materials for laboratory</del>-<del class="diffchange diffchange-inline">based analytical studies</del>. <del class="diffchange diffchange-inline">In this study</del>, <del class="diffchange diffchange-inline">histopathological evaluation </del>was performed to <del class="diffchange diffchange-inline">confirm </del>the <del class="diffchange diffchange-inline">possibility </del>of neurotoxicity <del class="diffchange diffchange-inline">of the tested substances by hematoxylin </del>and <del class="diffchange diffchange-inline">eosin staining method from collected brain samples</del>. In <del class="diffchange diffchange-inline">the present study</del>, <del class="diffchange diffchange-inline">we evaluated </del>the neurotoxicity of <del class="diffchange diffchange-inline">two </del>synthetic cannabinoids (<del class="diffchange diffchange-inline">JWH</del>-<del class="diffchange diffchange-inline">081 </del>and <del class="diffchange diffchange-inline">JWH</del>-<del class="diffchange diffchange-inline">210</del>) <del class="diffchange diffchange-inline">through observation </del>of <del class="diffchange diffchange-inline">various behavioral changes </del>and <del class="diffchange diffchange-inline">analysis </del>of <del class="diffchange diffchange-inline">histopathological changes using experimental mice </del>with <del class="diffchange diffchange-inline">various doses </del>(<del class="diffchange diffchange-inline">0</del>.1<del class="diffchange diffchange-inline">, 1, 5 mg/kg</del>). <del class="diffchange diffchange-inline">Selecting powder JWH</del>-<del class="diffchange diffchange-inline">210 demands careful evaluation </del>of <del class="diffchange diffchange-inline">purity</del>, <del class="diffchange diffchange-inline">legality, and supplier credibility. Prices for research</del>-<del class="diffchange diffchange-inline">grade JWH</del>-<del class="diffchange diffchange-inline">210 vary significantly based </del>on <del class="diffchange diffchange-inline">quantity, purity</del>, and <del class="diffchange diffchange-inline">vendor complianc</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">A total </ins>of <ins class="diffchange diffchange-inline">2 and 3 methamphetamine treated mice fell from </ins>the <ins class="diffchange diffchange-inline">spinning rod 30 min </ins>and <ins class="diffchange diffchange-inline">2 hr after </ins>the <ins class="diffchange diffchange-inline">administration</ins>, <ins class="diffchange diffchange-inline">respectively. After </ins>the <ins class="diffchange diffchange-inline">first injection, 6 mice </ins>of the <ins class="diffchange diffchange-inline">positive control group (methamphetamine</ins>, <ins class="diffchange diffchange-inline">5 mg</ins>/<ins class="diffchange diffchange-inline">kg</ins>, <ins class="diffchange diffchange-inline">i</ins>.<ins class="diffchange diffchange-inline">p</ins>.) <ins class="diffchange diffchange-inline">showed loss of traction</ins>, of <ins class="diffchange diffchange-inline">which 4 showed tremor</ins>. <ins class="diffchange diffchange-inline">Most of </ins>the <ins class="diffchange diffchange-inline">abnormalities were normalized </ins>in <ins class="diffchange diffchange-inline">synthetic cannabinoid treated mice although those abnormal behaviors remained </ins>in <ins class="diffchange diffchange-inline">methamphetamine treated animals after 2 hr </ins>of administration. <ins class="diffchange diffchange-inline">Brain samples </ins>were <ins class="diffchange diffchange-inline">prepared from the mice after the last administration </ins>of <ins class="diffchange diffchange-inline">test substance&lt;br&gt;</ins>&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">A 30</ins>-<ins class="diffchange diffchange-inline">min period</ins>, <ins class="diffchange diffchange-inline">beginning when maximal depression of locomotor activity first appeared as a function of dose</ins>, <ins class="diffchange diffchange-inline">was used for analysis of dose</ins>-<ins class="diffchange diffchange-inline">response data and calculation of ED50 values</ins>. <ins class="diffchange diffchange-inline">During test sessions, both levers were active, such that ten consecutive responses on either lever led to </ins>cannabinoidsrc4f-adb.com <ins class="diffchange diffchange-inline">reinforcement</ins>. The <ins class="diffchange diffchange-inline">substitution tests occurred only if </ins>the <ins class="diffchange diffchange-inline">rats had achieved 85% injection</ins>-<ins class="diffchange diffchange-inline">appropriate responding </ins>on the <ins class="diffchange diffchange-inline">two prior training sessions</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">The locomotor activity assay was used to identify approximate time courses and dose ranges </ins>of <ins class="diffchange diffchange-inline">psychoactive effects</ins>, which <ins class="diffchange diffchange-inline">is useful for identifying parameters for drug discrimination experiments and </ins>are <ins class="diffchange diffchange-inline">also predictive of the time course of the psychoactive effects </ins>in <ins class="diffchange diffchange-inline">human users</ins>. <ins class="diffchange diffchange-inline">The purpose of the present study was to assess </ins>the <ins class="diffchange diffchange-inline">abuse liability </ins>of <ins class="diffchange diffchange-inline">5F-MDMB-PINACA, MDMB</ins>-<ins class="diffchange diffchange-inline">CHIMICA, </ins>MDMB-<ins class="diffchange diffchange-inline">FUBINACA, ADB-FUBINACA</ins>, and <ins class="diffchange diffchange-inline">AMB-FUBINACA</ins>. <ins class="diffchange diffchange-inline">Since there is currently no robust measure of the reinforcing</ins>/<ins class="diffchange diffchange-inline">rewarding effects of cannabinoids</ins>, <ins class="diffchange diffchange-inline">drug discrimination is currently </ins>the <ins class="diffchange diffchange-inline">best model for assessing abuse liability of cannabinoids</ins>. <ins class="diffchange diffchange-inline">The findings produce an apparent paradox</ins>, <ins class="diffchange diffchange-inline">since CPP and self-administration predict with </ins>high <ins class="diffchange diffchange-inline">reliability the likelihood that a compound will be abused by humans</ins>, <ins class="diffchange diffchange-inline">and cannabinoids are well</ins>-<ins class="diffchange diffchange-inline">known </ins>to <ins class="diffchange diffchange-inline">produce active drug-seeking in </ins>human&lt;br&gt;&lt;br&gt;&lt;br&gt;This makes JWH-210 powder one of the most powerful compounds in its class, often used in incense blends and research settings. Our commitment to quality and customer satisfaction makes us the best place for jwh 210 buy-whether you need it for research, incense blends, or other legal applications. For qualified professionals, investing in high-quality, verified material ensures accuracy, safety, and regulatory compliance. Prioritize vendors providing full analytical validation, transparent documentation, and compliance with international controls. Value is best assessed through consistency, verifiable purity, and regulatory compliance—not cost alon&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">The current study indicates that </ins>the <ins class="diffchange diffchange-inline">test compounds produce locomotor depression similar to that of Δ9-THC</ins>, <ins class="diffchange diffchange-inline">and fully substitute </ins>for <ins class="diffchange diffchange-inline">the discriminative stimulus effects of Δ9-THC. In summary, these 5F-MDMB-PINACA</ins>, <ins class="diffchange diffchange-inline">MDMB-CHIMICA, MDMB-FUBINACA</ins>, <ins class="diffchange diffchange-inline">ADB-FUBINACA</ins>, and <ins class="diffchange diffchange-inline">AMB-FUBINACA have similar abuse liability as Δ9-tetrahydrocannabinol and should be controlled in a similar fashion. Much of the in vivo [https://cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb.com</ins>/ <ins class="diffchange diffchange-inline">cannabinoidsrc4f-adb.com] testing of the synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like effects or like the present study, focused on their abuse liability</ins>. <ins class="diffchange diffchange-inline">There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 </ins>and <ins class="diffchange diffchange-inline">CB2 (Wiley et al., 2016)</ins>, <ins class="diffchange diffchange-inline">and a </ins>compound <ins class="diffchange diffchange-inline">from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016&lt;br&gt;&lt;br&gt;&lt;br&gt;Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed </ins>by <ins class="diffchange diffchange-inline">one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at cannabinoidsrc4f</ins>-<ins class="diffchange diffchange-inline">adb</ins>.<ins class="diffchange diffchange-inline">com least three rats completed the first fixed ratio</ins>, <ins class="diffchange diffchange-inline">whereas all rats are shown for the response rate dat&lt;br&gt;&lt;br&gt;&lt;br&gt;Morris water maze test </ins>was performed to <ins class="diffchange diffchange-inline">evaluate the changes in learning and memory function. Only a few case reports about </ins>the <ins class="diffchange diffchange-inline">dangers </ins>of <ins class="diffchange diffchange-inline">some synthetic cannabinoids due to </ins>neurotoxicity <ins class="diffchange diffchange-inline">have been published (Cohen et al., 2012; McGuinness et al., 2012; Harris </ins>and <ins class="diffchange diffchange-inline">Brown, 2013; Hermanns et al., 2013)</ins>. In <ins class="diffchange diffchange-inline">addition</ins>, the <ins class="diffchange diffchange-inline">lack of information about </ins>neurotoxicity of synthetic cannabinoids <ins class="diffchange diffchange-inline">could allow abusers consume those substances undiscerningly. However, slight structural changes might cause biochemical properties including dependence liability and neurotoxicity. The substances used in the present study both possess naphthoylindole moiety as their parental structure. </ins>(<ins class="diffchange diffchange-inline">B) The ratio of damaged cells containing pyknotic or condensed nuclei and low hematoxilin affinity to total cells were calculated in nucleus accumben&lt;br&gt;&lt;br&gt;&lt;br&gt;High resolution mass spectrometry such as LC-QTOF</ins>-<ins class="diffchange diffchange-inline">MS allows the detection </ins>and <ins class="diffchange diffchange-inline">identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of</ins>-<ins class="diffchange diffchange-inline">care drugs of abuse (DOA</ins>) <ins class="diffchange diffchange-inline">test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption </ins>of <ins class="diffchange diffchange-inline">food </ins>and <ins class="diffchange diffchange-inline">using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack </ins>of <ins class="diffchange diffchange-inline">cigarettes a day and sometimes smokes e-cigarettes. Combined </ins>with <ins class="diffchange diffchange-inline">non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .&lt;br&gt;Data availability &lt;br&gt;The intensity is plotted against the retention time for both chromatograms, demonstrating the cannabinoidsrc4f-adb.com presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA </ins>(<ins class="diffchange diffchange-inline">Fig</ins>. 1). <ins class="diffchange diffchange-inline">Because the point</ins>-of<ins class="diffchange diffchange-inline">-care DOA test is generally not able to detect synthetic recreational drug substances</ins>, <ins class="diffchange diffchange-inline">the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC</ins>-<ins class="diffchange diffchange-inline">QTOF</ins>-<ins class="diffchange diffchange-inline">MS) </ins>on <ins class="diffchange diffchange-inline">the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER</ins>, <ins class="diffchange diffchange-inline">the nausea complaints of the patient were reduced </ins>and <ins class="diffchange diffchange-inline">the patient was discharged hom</ins></div></td></tr> </table>

MeghanPocock https://gate.unigre.it/mediawiki/index.php?title=5F-ADB-PINACA_Wikipedia&diff=148495&oldid=prev 2026-05-25T07:15:21Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 07:15, 25 May 2026</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">A limitation </del>of <del class="diffchange diffchange-inline">this case report is that we did not have a urine sample available for additional NPS testing</del>. <del class="diffchange diffchange-inline">Point-of-care DOA tests using urine </del>to <del class="diffchange diffchange-inline">screen for misuse </del>of <del class="diffchange diffchange-inline">multiple substances</del>, <del class="diffchange diffchange-inline">regularly include cannabis</del>, <del class="diffchange diffchange-inline">amphetamines, cocaine, opioids, benzodiazepines </del>and <del class="diffchange diffchange-inline">methadone</del>. <del class="diffchange diffchange-inline">THC</del>, <del class="diffchange diffchange-inline">methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine </del>are <del class="diffchange diffchange-inline">likely to become volatile under the temperature </del>of <del class="diffchange diffchange-inline">current e</del>-<del class="diffchange diffchange-inline">cigarettes, while crack cocaine is hard to vaporise</del>. <del class="diffchange diffchange-inline">A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">Thirty minutes prior to the training sessions</del>, <del class="diffchange diffchange-inline">rats received an injection of either vehicle or Δ9-THC and were subsequently placed in </del>the <del class="diffchange diffchange-inline">behavior-testing chambers</del>, <del class="diffchange diffchange-inline">where food (45</del>-<del class="diffchange diffchange-inline">mg food pellets; Bio</del>-<del class="diffchange diffchange-inline">Serve</del>, <del class="diffchange diffchange-inline">Frenchtown, NJ) was available as a reinforcer </del>for <del class="diffchange diffchange-inline">every ten responses (FR10) </del>on <del class="diffchange diffchange-inline">a designated injection appropriate leve&lt;br&gt;&lt;br&gt;&lt;br&gt;Such decrease remained 2 hr after </del>the <del class="diffchange diffchange-inline">administration </del>(<del class="diffchange diffchange-inline">Table 4</del>). <del class="diffchange diffchange-inline">In locomotor activity, methamphetamine treated group showed approximately 4.2 times increase compared </del>to the <del class="diffchange diffchange-inline">negative control treated group</del>. <del class="diffchange diffchange-inline">Change </del>of <del class="diffchange diffchange-inline">body weight following the treatments </del>with <del class="diffchange diffchange-inline">JWH</del>-<del class="diffchange diffchange-inline">081 </del>and <del class="diffchange diffchange-inline">JWH-210 in mic</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Locomotor activity </del>in <del class="diffchange diffchange-inline">mice was tested to screen </del>for <del class="diffchange diffchange-inline">locomotor depressant effects </del>and to <del class="diffchange diffchange-inline">identify behaviorally-active dose ranges </del>and <del class="diffchange diffchange-inline">times </del>of <del class="diffchange diffchange-inline">peak </del>effect. <del class="diffchange diffchange-inline">Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known </del>to have <del class="diffchange diffchange-inline">substantial abuse liability </del>and <del class="diffchange diffchange-inline">act </del>at <del class="diffchange diffchange-inline">the CB1 receptor. Tremors were not observed following AMB-FUBINACA during the drug discrimination study</del>, but the <del class="diffchange diffchange-inline">maximum dose tested was only 0.1 mg/kg</del>, <del class="diffchange diffchange-inline">which is 10-fold lower than the dose that produced tremors </del>in <del class="diffchange diffchange-inline">the mice</del>. <del class="diffchange diffchange-inline">AMB</del>-<del class="diffchange diffchange-inline">FUBINACA has been implicated </del>in <del class="diffchange diffchange-inline">severe adverse effects in recreational users (Adams et al</del>.<del class="diffchange diffchange-inline">, 2017; Hamilton et al</del>.<del class="diffchange diffchange-inline">, 2017)</del>, which <del class="diffchange diffchange-inline">suggests that the range between behaviorally active and toxic doses of AMB-FUBINACA is narrow</del>. <del class="diffchange diffchange-inline">Following that line of reasoning, it should also be noted that some of </del>the <del class="diffchange diffchange-inline">more recent compounds produced non-linear </del>dose-<del class="diffchange diffchange-inline">effect curves and one compound produced an inverted U</del>-<del class="diffchange diffchange-inline">shaped dose-effect</del>, <del class="diffchange diffchange-inline">such that intermediate dose fully substituted, but higher doses did not (Gatch </del>and <del class="diffchange diffchange-inline">Forster, 2018)</del>. <del class="diffchange diffchange-inline">All of </del>the <del class="diffchange diffchange-inline">compounds identified as available on </del>the <del class="diffchange diffchange-inline">recreational market and submitted to our laboratory by </del>the <del class="diffchange diffchange-inline">US Drug Enforcement Agency for testing </del>have <del class="diffchange diffchange-inline">fully substituted </del>at <del class="diffchange diffchange-inline">some dose (Gatch and Forster 2014, 2015, 2016</del>, <del class="diffchange diffchange-inline">2018); however; it is important to note that not all structural congeners are active (Wiley et al., 2012</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">The % peak area abundance ratio of metabolites detected in the urine samples </del>are <del class="diffchange diffchange-inline">often affected by numerous factors such as drug intake behaviour (intake route</del>, <del class="diffchange diffchange-inline">amount of drug </del>and <del class="diffchange diffchange-inline">intake frequency</del>), <del class="diffchange diffchange-inline">time from last drug intake and metabolic stabilit</del>&lt;br&gt;&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">LC separates </del>the <del class="diffchange diffchange-inline">urine or blood sample </del>and <del class="diffchange diffchange-inline">QTOF-MS provides high-resolution </del>and <del class="diffchange diffchange-inline">accurate mass measurements </del>for <del class="diffchange diffchange-inline">precise identification and structural elucidation of compounds. The LC</del>-<del class="diffchange diffchange-inline">QTOF-MS method offers a more comprehensive and sensitive approach </del>for <del class="diffchange diffchange-inline">drug detection</del>, <del class="diffchange diffchange-inline">covering hundreds of recreational drugs</del>, <del class="diffchange diffchange-inline">including NPS</del>. <del class="diffchange diffchange-inline">Besides increasing the temperature to enlarge the drug aerolisation and bioavailability</del>, <del class="diffchange diffchange-inline">one can elevate the flow rate of air through the e</del>-<del class="diffchange diffchange-inline">cigarette </del>and<del class="diffchange diffchange-inline">/or add a diluent </del>. <del class="diffchange diffchange-inline">Of all e-cigarette users registered at this forum</del>, <del class="diffchange diffchange-inline">7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong</del>, <del class="diffchange diffchange-inline">together </del>with <del class="diffchange diffchange-inline">synthetic opioids</del>, <del class="diffchange diffchange-inline">cathinones</del>, <del class="diffchange diffchange-inline">amphetamines </del>and <del class="diffchange diffchange-inline">hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.</del>&lt;br&gt;<del class="diffchange diffchange-inline">Data availabili</del>&lt;br&gt;&lt;br&gt;<del class="diffchange diffchange-inline">&lt;br&gt;Thirty minutes prior to </del>the <del class="diffchange diffchange-inline">training sessions</del>, <del class="diffchange diffchange-inline">rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-</del>testing <del class="diffchange diffchange-inline">chambers</del>, <del class="diffchange diffchange-inline">where food (45</del>-<del class="diffchange diffchange-inline">mg food pellets; Bio-Serve</del>, <del class="diffchange diffchange-inline">Frenchtown, NJ) was available as a reinforcer </del>for <del class="diffchange diffchange-inline">every ten responses (FR10) on a designated injection appropriate lever</del>. <del class="diffchange diffchange-inline">A houselight </del>was <del class="diffchange diffchange-inline">centered over </del>the <del class="diffchange diffchange-inline">hopper close to </del>the <del class="diffchange diffchange-inline">ceiling </del>and <del class="diffchange diffchange-inline">was illuminated only when </del>the <del class="diffchange diffchange-inline">levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty</del>-<del class="diffchange diffchange-inline">four male Sprague</del>-<del class="diffchange diffchange-inline">Dawley rats were obtained from Envigo </del>(<del class="diffchange diffchange-inline">Houston</del>, <del class="diffchange diffchange-inline">TX</del>). <del class="diffchange diffchange-inline">[https://cannabinoidsrc4f</del>-<del class="diffchange diffchange-inline">adb.com/ 5CLADBA] Male ND4 Swiss–Webster mice were obtained from Envigo (Houston</del>, <del class="diffchange diffchange-inline">TX) at approximately 8 weeks of age </del>and <del class="diffchange diffchange-inline">maintained in the University of North Texas Health Science Center (UNTHSC) animal facility </del>for <del class="diffchange diffchange-inline">two weeks prior to testin&lt;br&gt;&lt;br&gt;&lt;br&gt;The same procedure was then applied to the mice once every day for 5 days. It was considered as coordination disturbance when mice fell from the test apparatus within 2 min. Mice that remained their position </del>on <del class="diffchange diffchange-inline">the running apparatus at 10 rpm for at least 2 min were selected for further evaluation.&lt;br&gt;Table of Conten</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">Due to the unknown toxicity </ins>of <ins class="diffchange diffchange-inline">newly emerging SCRAs, forensic assessments of cases involving these substances are challenging</ins>. <ins class="diffchange diffchange-inline">According </ins>to <ins class="diffchange diffchange-inline">the reported cases and reviews </ins>of <ins class="diffchange diffchange-inline">the scientific literature</ins>, <ins class="diffchange diffchange-inline">concurrent ethanol consumption should amplify the toxicity of SCRAs. The concentration of 4F-MDMB-BINACA in the postmortem blood was 2.50 and 2.34 ng/mL</ins>, and <ins class="diffchange diffchange-inline">blood alcohol concentration was 2.11 and 2</ins>.<ins class="diffchange diffchange-inline">49 g/L</ins>, <ins class="diffchange diffchange-inline">respectively. Two fatal cases </ins>are <ins class="diffchange diffchange-inline">reported caused by simultaneous consumption </ins>of <ins class="diffchange diffchange-inline">4F</ins>-<ins class="diffchange diffchange-inline">MDMB-BINACA and ethanol</ins>.&lt;br&gt;<ins class="diffchange diffchange-inline">Fig. 2. </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">The precursor ion m/z 396 (B10</ins>, <ins class="diffchange diffchange-inline">B12/B15) was 32 Da higher than </ins>the <ins class="diffchange diffchange-inline">parent drug</ins>, <ins class="diffchange diffchange-inline">4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA</ins>, <ins class="diffchange diffchange-inline">suggesting the addition of two hydroxy groups. All the below explanations </ins>for <ins class="diffchange diffchange-inline">transformations into metabolites are based </ins>on the <ins class="diffchange diffchange-inline">data shown in Fig. Metabolites were identified according to their precursor ions, product ions, and fragmentation patterns </ins>(<ins class="diffchange diffchange-inline">Fig. 1</ins>). <ins class="diffchange diffchange-inline">Traditional in-vivo metabolism studies </ins>to <ins class="diffchange diffchange-inline">generate human metabolites of drugs relied heavily on </ins>the <ins class="diffchange diffchange-inline">use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues</ins>. <ins class="diffchange diffchange-inline">Eight in-vivo metabolites tentatively identified were mainly products </ins>of <ins class="diffchange diffchange-inline">ester hydrolysis </ins>with <ins class="diffchange diffchange-inline">or without additional dehydrogenation, N</ins>-<ins class="diffchange diffchange-inline">dealkylation, monohydroxylation </ins>and <ins class="diffchange diffchange-inline">oxidative defluorination with further oxidation to butanoic acid.</ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Fig. 1. </ins>&lt;br&gt;<ins class="diffchange diffchange-inline">Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed </ins>in <ins class="diffchange diffchange-inline">cultured hepatoma cell line, fungus, [https://cannabinoidsrc4f-adb.com/ cannabinoidsrc4f-adb.com] liver microsomes and confirmed using urine samples The threshold </ins>for <ins class="diffchange diffchange-inline">fatal overdose of combined use of SCRAs </ins>and <ins class="diffchange diffchange-inline">ethanol can be estimated as a little ng/mL (0.37–4.1 ng/mL according </ins>to <ins class="diffchange diffchange-inline">the reported cases) of SCRA and 1.5–2.5 g/L of ethanol. The reported cases </ins>and <ins class="diffchange diffchange-inline">reviews </ins>of <ins class="diffchange diffchange-inline">the scientific literature suggest a possible synergistic </ins>effect <ins class="diffchange diffchange-inline">between SCRAs and ethanol, because their combined use clearly increases their toxicity</ins>. <ins class="diffchange diffchange-inline">The victim died due </ins>to <ins class="diffchange diffchange-inline">severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission . Studies </ins>have <ins class="diffchange diffchange-inline">found no unequivocal synergistic effect between THC </ins>and <ins class="diffchange diffchange-inline">ethanol </ins>at <ins class="diffchange diffchange-inline">low or moderate ethanol doses [29, 30]</ins>, but <ins class="diffchange diffchange-inline">no data on high doses of ethanol are available. Given that THC and ethanol act on </ins>the <ins class="diffchange diffchange-inline">same receptors</ins>, <ins class="diffchange diffchange-inline">data on their simultaneous use may yield important insights </ins>in <ins class="diffchange diffchange-inline">this regard.&lt;br&gt;Fungus C</ins>. <ins class="diffchange diffchange-inline">elegans &lt;br&gt;Concentrations of 4F</ins>-<ins class="diffchange diffchange-inline">MDMB-BINACA </ins>in <ins class="diffchange diffchange-inline">the postmortem blood samples were 2</ins>.<ins class="diffchange diffchange-inline">50 and 2</ins>.<ins class="diffchange diffchange-inline">34 ng/mL</ins>, which <ins class="diffchange diffchange-inline">are in line with published data</ins>. <ins class="diffchange diffchange-inline">Although </ins>the <ins class="diffchange diffchange-inline">lethal </ins>dose <ins class="diffchange diffchange-inline">of 4F</ins>-<ins class="diffchange diffchange-inline">MDMB</ins>-<ins class="diffchange diffchange-inline">BINACA is unknown</ins>, <ins class="diffchange diffchange-inline">its concentration in postmortem blood samples was found to range between 0.10 </ins>and <ins class="diffchange diffchange-inline">2.90 ng/mL </ins>. <ins class="diffchange diffchange-inline">In SCRA-related cases in which </ins>the <ins class="diffchange diffchange-inline">deceased suffered from heart disease, </ins>the <ins class="diffchange diffchange-inline">SCRA concentration in </ins>the <ins class="diffchange diffchange-inline">postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival </ins>have <ins class="diffchange diffchange-inline">also been published—even </ins>at <ins class="diffchange diffchange-inline">relatively high blood SCRA concentrations [19</ins>, <ins class="diffchange diffchange-inline">20</ins>&lt;br&gt;&lt;br&gt; <ins class="diffchange diffchange-inline">In-vitro metabolism studies </ins>are <ins class="diffchange diffchange-inline">generally used to complement these data using perfused organs</ins>, <ins class="diffchange diffchange-inline">tissue or cell cultures </ins>and <ins class="diffchange diffchange-inline">microsomal preparations amongst which pooled human liver microsomes (HLM</ins>) <ins class="diffchange diffchange-inline">have been frequently used to elucidate metabolism of SCBs [12</ins>,<ins class="diffchange diffchange-inline">13,14,15,16</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">This makes JWH-210 powder one of </ins>the <ins class="diffchange diffchange-inline">most powerful compounds in its class, often used in incense blends </ins>and <ins class="diffchange diffchange-inline">research settings. Our commitment to quality </ins>and <ins class="diffchange diffchange-inline">customer satisfaction makes us the best place </ins>for <ins class="diffchange diffchange-inline">jwh 210 buy</ins>-<ins class="diffchange diffchange-inline">whether you need it </ins>for <ins class="diffchange diffchange-inline">research</ins>, <ins class="diffchange diffchange-inline">incense blends</ins>, <ins class="diffchange diffchange-inline">or other legal applications</ins>. <ins class="diffchange diffchange-inline">For qualified professionals</ins>, <ins class="diffchange diffchange-inline">investing in high</ins>-<ins class="diffchange diffchange-inline">quality, verified material ensures accuracy, safety, </ins>and <ins class="diffchange diffchange-inline">regulatory compliance</ins>. <ins class="diffchange diffchange-inline">Prioritize vendors providing full analytical validation</ins>, <ins class="diffchange diffchange-inline">transparent documentation</ins>, <ins class="diffchange diffchange-inline">and compliance </ins>with <ins class="diffchange diffchange-inline">international controls. Value is best assessed through consistency</ins>, <ins class="diffchange diffchange-inline">verifiable purity</ins>, and <ins class="diffchange diffchange-inline">regulatory compliance—not cost alon</ins>&lt;br&gt;&lt;br&gt;&lt;br&gt;<ins class="diffchange diffchange-inline">In </ins>the <ins class="diffchange diffchange-inline">present study</ins>, <ins class="diffchange diffchange-inline">we performed various methods based on animal behavioral </ins>testing <ins class="diffchange diffchange-inline">including FOB test for general behavioral observation</ins>, <ins class="diffchange diffchange-inline">rotarod test, locomotor activity test for motor function evaluation, and water</ins>-<ins class="diffchange diffchange-inline">maze test for learning/memory evaluation. Known for its stability and consistent composition</ins>, <ins class="diffchange diffchange-inline">this compound is frequently utilized by professionals seeking reliable materials </ins>for <ins class="diffchange diffchange-inline">laboratory-based analytical studies</ins>. <ins class="diffchange diffchange-inline">In this study, histopathological evaluation </ins>was <ins class="diffchange diffchange-inline">performed to confirm </ins>the <ins class="diffchange diffchange-inline">possibility of neurotoxicity of </ins>the <ins class="diffchange diffchange-inline">tested substances by hematoxylin </ins>and <ins class="diffchange diffchange-inline">eosin staining method from collected brain samples. In the present study, we evaluated </ins>the <ins class="diffchange diffchange-inline">neurotoxicity of two synthetic cannabinoids (JWH</ins>-<ins class="diffchange diffchange-inline">081 and JWH</ins>-<ins class="diffchange diffchange-inline">210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses </ins>(<ins class="diffchange diffchange-inline">0.1</ins>, <ins class="diffchange diffchange-inline">1, 5 mg/kg</ins>). <ins class="diffchange diffchange-inline">Selecting powder JWH</ins>-<ins class="diffchange diffchange-inline">210 demands careful evaluation of purity, legality</ins>, and <ins class="diffchange diffchange-inline">supplier credibility. Prices </ins>for <ins class="diffchange diffchange-inline">research-grade JWH-210 vary significantly based </ins>on <ins class="diffchange diffchange-inline">quantity, purity, and vendor complianc</ins></div></td></tr> <!-- diff cache key my_wiki:diff::1.12:old-148439:rev-148495 --> </table>

LawrenceOLeary9